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ABSTRACT
Calcitonin plays a critical role in preventing excessive bone resorption during lactation.
Mice lacking both copies ofthc calcitonin (CT) gene (CT null mice) lose 55% ofbonc
mineral content (BMC) or twice the amount of wildtype mice during lactation. Thc
calcitonin receptor (CTR) is expressed in the pituitary, lactating breast tissues and bone in
micc. However, at which of the three tissues and through which mechanisms the
calcitonin acts on CTR to regulate calcium metabolism during rcproductive periods arc
still unclear. This project assesses mice lacking one copy ofa CTR gene as a means to
understand whethcr loss ofCTR has the same phenotypc as the loss ofCT during thc
reproductive cycle. (fso, it would enable more studies into thc detailed mechanisms of
how calcitonin works in each tissue during the reproductive period.
Wildtype (WT) and hcterozygous Or gene-deleted sistcrs (Or+I-) were used to comparc
BMC changes during pregnancy and lactation using the PixiMus DXA bone densitomcter.
Or null mice cannot be studied because they usually die prior to birth. Urine, serum and
milk were collected and analyzed for the mineral content, bone formation, bone
resorption markers, and parathyroid hormone (PTH). DXA scanning and urine/serum
collections occurred at baseline (before pregnancy), latc pregnancy, late lactation, and
days 7, 14 and 21 of post-weaning recovery. Tibias were analyzed separately by micro-
computed tomography (fACT), the 3-point bend test, and real-time quantitative RT-PCR
for Or gene expression.
WT and Or+l• mice experienced typical lactational changes of BMC and bone
microstructure and recovered quickly and fully to baseline levels after weaning. WT and
Or+l. females lost 10.7% ± 3.4% and 10.6% ± 2.0% BMC during lactation relative to
baseline level respectively. No significant difference in BMC was observed between WT
and Or+l. mice at any time point. Urine calcium, phosphorus and magnesium levels
changed appropriately during reproduction with no significant differences between WT
and C/i·+I., except for significantly lower urine phosphorus (11.0 ± 2.2 ofWT vs. 4.4 ± 1.4
of C/i·+I., p < 0.05) and a trend for lower urine calcium and magnesium in Or+l- at late
pregnancy. Bone turnover was increased in both genotypes at late lactation and early
recovery. PTH showed an increasing trend from baseline to late lactation. Milk calcium
content was the same in both genotypes. Bone strength was significantly decreased at late
lactation with no difference between genotypes. WT and Or+l• had equal levels of Or
mRNA expression in the tibia.
In summaIy, WT and Or+l• underwent similar changes in bone mass, bone
mieroarchitecture, ealeiotropic hormones, and serum and urine minerals during pregnancy
and lactation. After lactation, the skeleton of each genotype recovered fully and quickly.
Loss of one copy of the calcitonin receptor gene does not cause the same phenotype as
complete loss of the calcitonin gene (Ocgrp), likely because one allele transcription of
Or gene compensates.
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1 Introduction
1.1 Bone and mineral homeostasis
1.1.1 Bone
Bone plays physiologically essential roles in vertebrate animals. It protects internal
organs, provides frames to which internal organs can attach, and is a reservoir of minerals
such as calcium, phosphorus and magnesium.
1.1.1.1 Bone structure and composition
Morphologically, bone can be divided into two forms: cortical and cancellous (also called
trabecular). Cortical bone exists on the outer shell of most bones and accounts for 80% of
the weight of the human skeleton; cancellous bone is located in the interior of bone and
contributes to the rest of the human skeleton's weight (I). Cancellous bone has a looser
and more porous structure than cortical bone. The ratio of surface to vol umc in cancellous
bone is much greater than that in cortical bone, thus enabling cancellous bone to be
readily resorbed by osteoclasts and to be more physiologically active, such as releasing
alkali or minerals when needed. The different morphology of the two forms of bone leads
to different primary functions: Cortical bone provides support and protection of internal
organs while cancellous bone provides metabolic functions (2). Both forms contribute to
the overall strength of bone.
Bone contains 4 types of cells: osteoblasts, osteoclasts, bone lining cells and osteocytes.
Osteoblasts differentiate from mesenchymal precursor cells (3), which exist at thc bonc
surface. Unlike osteoblasts, osteoclasts belong to the monocyte/macrophage family and
are derived from hematopoietic stem cells (HSCs) (4). Bone lining cells are nat and
inactive, covering the non-remodeling surface of bone. They may become reactivated as
osteoblasts. Osteocytes are derived from osteoblasts, which form bone and account for 90
- 95% of all bone cells in a human adult skeleton (5). Unlike osteoblasts, osteoclasts, and
bone lining cells, osteocytes exist in the interior of bone.
1.1.1.2 Bone remodeling
Bone is continuously remodeled during life with simultaneous bone formation and
resorption. Bone remodeling provides many benefits in vivo: it releases calcium from
bone into serum to maintain calcium homeostasis, repairs micro fractures that occur from
daily physical activities, and replaces old bone. Bone remodeling has its own uniquc
structure called the Bone Remodeling Compartment (BRC) (6). The BRC is covcrcd by
lining cclls, which have similar characteristics to bone lining cells, and mainly consists of
osteoclasts at the forward (cutting/drilling) end, with osteoblasts following after (sec
Figure I). This structure enables bone remodeling to work cfficiently to maintain normal
bone physiological activities.
Lining cells
Figure 1: Model of Bone Remodeling Compartment (B1lC). BRC mainly consists of
lining cells, osteoblasts, and osteoclasts. Osteoblasts follow osteoclasts. The black arrow
indicates the direction of movement of the osteoclasts.
1.1.1.2.1 Osteoblast
Osteoblasts form new bone. As new bone is formed, mesenchymal stem cells differentiatc
toward mature osteoblasts. These osteoblasts proliferate and lay down extracellular
matrices (ECM), which then becomes mineralized (7). Any factors affecting ostcoblast
differentiation will affect bone formation. Runx2 (Cbfal) is a transcription factor that
triggers downstream cell signal cascades to express osteoblast specific genes, such as typc
I Collagen (Coil), alkaline phosphatase (ALP), osteopontin (OPN), osteonectin (ON) and
osteocalcin (3). The critical importance of Runx2 for osteoblasts and bone formation was
shown by RUl1xT1- mice, which died of respiratory failure due to lack of osteoblasts, bone,
and, therefore, a solid rib cage (8). However, Runx2 is not the only regulator. Ostcrix is
downstream ofRunx2 in the mesenchymal stem cell differentiation pathway (9). Absence
of Osterix can also lead to deficiencies during bone formation (10). Runx2 and the
Runx2/0sterix pathway function together to support bone formation through regulation of
osteoblast differentiation. Besides these two major regulators, Runx2 and Osterix, there
are still other factors that participate in the regulation of osteoblast differentiation. For
example, bone morphogenic proteins, which belong to TGF-~ superfamily, have a
positive effect on osteoblast differentiation by increasing bone formation (11, 12).
1.1.1.2.2 Osteoclast
A primary function of osteoclasts is to resorb bone through the production of powerful
enzymes and acids. Bone resorption by osteoclasts requires tight physical contact between
osteoclasts and bone matrices using integrin av~3 to create a sealed zone under the
osteoclast (13), and the formation ofa microenvironment with a pH as low as 4.5,
established by proton pumps and Chloride (Cr) Channels (4). The acidified environmcnt
releases the mineral content in bone and exposes the organic matrix that is mainly madc
of type I collagen. Type I collagen is further degraded by the lysosomal enzymc
cathepsinK.
Osteoclast differentiation is related to bone resorption activitics. The two major cylokincs
that regulate differentiation are Macrophage-Colony Stimulating Factor (M-CSF or CSF-
I) and Receptor Activator ofNF-K13 Ligand (RANKL). M-CSF itself induces thc
formation of osteoclast progenitors from hematopoietic stem cells (HSCs) (14, 15).
RANKL is an esscntial factor for the differentiation of osteoclasts, from small cclls to
large multinucleated mature osteoclasts. By binding to its receptor (RANK), RANKL
increases the expression of several osteoclast-specific genes to induce osteoclast
differentiation (15). Osteoprotegerin (OPG) inhibits the RA KlRA KL pathway by
acting as a high affinity dccoy receptor to RA KL. The ratio of RANKL to OPG is a kcy
factor in osteoclast formation and the regulation of bone resorption (4). In addition to thc
two key cytokines M-CSr and RANKL, other molecules such as interleukin (IL)-I,
parathyroid hormone (PTI-l), PTH-related peptide (PTI-!rP), and calcitriol also regulate the
differentiation of osteoclasts (16-18). The calcitonin receptor is expressed at the surl~lce
of osteoclasts, indicating that calcitonin has certain roles in osteoclasts (19). Onc study
showed that calcitonin could inhibit both osteoclast formation and multinucleated
osteoclast formation by activating the cAMP-PKA pathway, which stimulatcd thc
phosphorylation of Extracellular signal-regulated kinase 1/2 (ERK 1/2) (activated form),
and inducing Epac, which activated ERKI/2 (20). However, the full mechanism of how
calcitonin inhibits osteoclasts is still unclear. The function of calcitonin will be further
discussed in the Calcitonin Section (1.1.2.6).
1.1.1.2.3 Osteocyte
Osteocytes form from osteoblasts which become embedded in the bone matrix and
communicate with each other through thousands of canaliculi, much likc neurons
communicate with each other (21). Generally speaking, osteocytes are the master
controllers of bone remodeling. Osteocytes regulate bone remodeling by sensing thc
loading force and then send bone formation signals to recruit osteoblasts (22). Osteocyte-
ablated mice are resistant to unloading (tail suspension)-induced bone resorption, which
suggests that it is the osteocyte that senses loading force (23). Osteoclast activity is
inhibited by osteocyte-like cell conditioned medium, and the inhibitory effect enhanccd
by estrogen is due to TGF-~3 being secreted by the osteocyte-like cells (24). Ablation of
osteocytes increases osteoclast activity dramatically in vivo, resulting in high levels of
bone resorption (23). Osteocyte death and apoptosis also stimulate bone resorption.
Mirco-damage and micro-cracks are thought to break canaliculi, thus physically
damaging osteocytes and then causing osteocyte apoptosis. This was shown in the
observation of apoptotic osteocytes at micro-damage sites in vivo (25). Simultaneous
osteocyte apoptosis and unloading send signals to recruit and activate osteoclasts to
increase bone resorption (5, 26).
1.1.2 Calcium homeostasis
Bone is the main calcium storage site of the body. Ninety-nine percent of calcium is
stored in bone as hydroxyapatite crystals in the human body. The remaining I% of
calcium exists in blood, extracellular fluid, and soft tissue (27). Gfthe calcium in blood,
45% is bound to albumin, 10% is bound to small molecules such as phosphate and citrate,
and the remaining 45% is free or ionized in a biologically active form (27). Ionized
calcium is maintained at a stable level in vivo due to the action of the Ca2+-sensing
receptor (CaSR).
1.1.2.1 CaSR
The CaSR is expressed by the parathyroids, kidneys, intestine, thyroid gland, and bone
(28). The primary function of this receptor is to sense the ionized calcium (Ca2+)
concentration and maintain it at a constant level in vivo. The CaSR appears to regulate the
cells and tissues that are needed to increase or decrease serum calcium For example, it
inhibits parathyroid hormone (PTH), increases urine calcium excretion, stimulates
calcitonin, and probably alters osteoclast and osteoblast activity (29). The biologically
active form of the CaSR is a dimer at the cell surface. The dimer is not formed until Ca2+
concentration in extracellular fluid (ECF) is high (30). Activation of the CaSR induces
several G-protein mediated pathways, including mitogen-activated protein kinase
(MAPK) cascades. ERK 1/2 and Jun N-terminal kinase (JNK) are translocated into the
nucleus to modifY targeted gene expression (31). A high Ca2+ concentration in ECF can
reduce PTH gene expression and stimulate calcitonin release.
1.1.2.2Calcitriol
Calcitriol, also known as 1,25-dihydroxyvitamin DJ , plays an essential role in maintaining
calcium homeostasis in vivo. It is the biologically active form of Vitamin DJ . The kcy
cnzyme involved in this conversion process is 25-hydroxyvitamin D-I a hydroxylasc
[la(OH)ase] which converts 25-hydroxy-Vitamin DJ into calcitrio1. Calcitriol belongs to
the steroid hormone family and acts on Vitamin D receptors (VDR) locatcd in the
cytoplasm. Once calcitriol binds to VDR, the complex enters the nuclei of cells and forms
a heterodimer with the retinoid X receptor (RXR) to activate Vitamin D target gencs (32).
The classical target tissues of calcitrioI are bone, intestine, and kidney. Calcitriol's main
cffects on bone are thought to be indirect, stimulating thc absorption of calcium and
phosphorus from the intestine. Studies in humans and animals have shown that the
skelctal effects of severe vitamin D deficiency or absence of the vitamin D receptor can
be completely reversed by intravenous calcium infusions or a high calcium diet (33, 34).
However, in vitro experiments have shown that calcitriol can stimulate bone formation
and resorption. On one hand (bone formation), it increases thc level of calcium-binding
proteins, osteocalcin, and osteopontin in osteoblasts (35, 36). Elevated osteocalcin and
osteopontin accelerate the process of mineralization to form new bone. On the other hand
(bone resorption), RANKL expression at the surface of osteoblasts is cnhanced by
calcitrio1. Physical cell-to-cell contact between osteoblasts with high RANKL and
ostcoclast precursors induces more osteoclast formation, thus increasing bone resorption
(37). Runx2 expression is also suppressed by calcitriol to reducc osteoblast differentiation
(38). The net effect of calcitriol's direct actions on osteoblasts and osteoclasts may be
small or even neutral in vivo. However, these actions may explain why extremely high
lcvcls of calcitriol can cause significantly increased bone resorption in patients with
sarcoidosis or hypervitaminosis 0 (39, 40).
In the kidneys, calcitriol enhances PTI-l's effect on calcium reabsorption in distal tubules
by increasing PTI-l receptor expression (41). The function of PTI-l on calcium
reabsorption in the kidneys will bc discussed in the Kidney Scction 1.1.2.4. Calcitriol also
incrcases renal cxpression of calcium-binding proteins (calbindins) (42). The increascd
calbindins transfer more calcium from the lumen in distal tubule to blood; therefore, morc
calcium is reabsorbed. However, calcitriol inhibits la(OI-l)ase activity and stimulatcs thc
catabolic enzyme 24-hydroxylase (43). These mechanisms make sure that the calcitriol
level in vivo is maintained within a normal range.
The effect of calcitriol on the intestine will be discussed in the Intestine Scction 1.1.2.5.
1.1.2.3 Parathyroid gland
Parathyroid glands play an important role in calcium homeostasis in vivo-they secrcle
PTI-1. PTI-I is a key factor in regulating calcium homeostasis in vivo as it regulates bone
formation and resorption, increases reabsorption of calcium and excretion of phosphorus
by kidney tubules, and indirectly stimulates intestinal calcium absorption by incrcasing
rcnal expression of 1a hydroxylase to form calcitriol (44). The function of PTI-I is
coupled with the expression of the CaSR at the surface of chief cells in parathyroid glands.
Activation of the CaSR by a high serum calcium level inhibits PTI-I synthcsis, sccrction,
and parathyroid cell growth. When a low serum calcium concentration is present, CaSR is
not activated, and so more PTH will be produced and released to raise blood calcium.
In bone, the PTH/PTHrP receptor (PTHR) is expressed by osteoblasts. However, the
actions ofPTH are complex. In response to PTH, osteoblast apoptosis is inhibited. I\s
wcll, osteoblasts proliferate, and their activity is increased to lay down matrix and (orm
bone; in the absence ofPTH, osteoblasts are inactive and little new bone is formed (45).
I\lso in response to PTH, osteoblasts are stimulated to produce RANKL, which binds to
RANK on the surface of osteoclast precursors and mature osteoclasts. As discussed above,
the net effect of this means increased numbers of mature osteoclast cells that are recruitcd
to the bone surface to resorb bone. PTH also reduces osteoblasts' expression ofOPG (46,
47), thus making the ratio of RANKL to OPG high. Which of these opposing actions of
PTH predominates (to stimulate bone formation or, conversely, to stimulate bone
resorption) may depend upon the circulating level ofPTH or some aspect of the
magnitude and frequency of its pulsed release. This has been confirmed by experiments in
animals that demonstrated that one- or two-hour infusions ofPTI-[ increased osteoblast
activity without affecting osteoclast activity, while longer infusions of PTH markedly
increased osteoclast activity (48). Also, once-daily injections of PTI-I markedly stimulated
bone formation and led to a massive increase in bone mass (47, 49). In humans, once-
daily subcutaneous injections of PTH induce net bone formation and have become a
standard treatment for osteoporosis, while chronically elevated PTH due to primary or
secondary hyperparathyroidism leads to increased bone resorption and net bone loss (50-
52). Therefore, it is evident that PTI-I's opposing actions on osteoblasts may depend upon
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the magnitude and frequency of its release, but the detailed mechanisms of this
relationship are still unclear.
The function of PTE in both the kidney and the intestine will be discussed in the
following Kidney Section 1.1.2.4 and Intestine Section 1.1.2.5.
1.1.2.4 Kidney
The kidneys regulate calcium balance by reabsorbing and excreting calcium. Sixty-five
percent of filtered calcium is reabsorbed at proximal tubules, 20% at cortical thick
ascending limbs (CTAL), and the remaining 15% at distal convoluted tubules (OCT) (27).
PTH has no effect on calcium reabsorption at the proximal tubules. In CTAL, calcium
reabsorption is driven by the Na-2CI-K cotransporter. The cotransporter mainly regulates
NaCI reabsorption, but the electrochemical gradient formed by NaCI reabsorption enablcs
calcium to be reabsorbed. PTI-I increases calcium reabsorption at the CTAL by enhancing
the activity of the Na-2CI-K cotransporter (53,54). Conversely, the CaSR inhibits the
overall activity of the Na-2CI-K cotransporter at the CTAL such that less calcium is
reabsorbcd. In the OCT, calcium reabsorption is an active and transcellular process
enabled by several Ca-transporting proteins including transient receptor potcntial
vanilloid type 5 (TRPV5), TRPV6, plasma membrane calcium ATPase (PMCAlb),
sodium-calcium exchanger (NCX I) and calbindin-D28K (55). NCXl is a ubiquitously
expresscd cell membrane protein that trades three sodium ions for one calcium ion. PTl-l
primarily increases the activity ofNCXI at OCT (27), thus causing increased sodium
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excretion to enable more calcium to be absorbed. It is unclear whether the CaSR has any
actions of calcium reabsorption at the OCT (28).
The effect of PTH on renal calcium reabsorption might seem insignificant given that 65%
of calcium is reabsorbed in the proximal tubules independently of PTI-I, and that the
CaSR has actions which oppose PTH in CTAL (27, 56). However, the critical importance
of PTI-I on renal calcium handling is made clear by what happens when PTI-I
concentrations are low or absent, such as in hypoparathyroidism: the serum calcium
becomes very low, which should prompt the kidneys to avidly conserve calcium, but
instead urine calcium excretion increases markedly, thereby worsening the calcium deficit
and hypocalcemia (57).
1.1.2.5 Intestine
The intestines absorb calcium from the diet. Ninety percent of this absorption occurs at
the duodenum and jejunum in humans, and the duodenum in mice. This absorption
includes passive, paracellular and active, transcellular mechanisms. The passive pathway
is driven by electrochemical gradients caused by high Ca2+ concentration of l-5x IO·3M in
the intestinal lumen and low ci+ concentration of IO-3M in blood. This pathway is
utilized by administering a high calcium diet to bypass the effect of the absence of
calcitriol. The active pathway involves membrane receptors and cytosol binding proteins.
Ca2+ concentration differences between intestinal lumen (1-5 x lO-3M) and cytosol (I0·6M)
force calcium into intestinal epithelial cells through the calcium channel TRPV6, also
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known as CATl or ECaC2, at the cell membrane (58-60). Once calcium is absorbed into
epithelial cells, it is bound to Calbindin-D9K and other calbindins, which carry calcium
from the apical membrane to the basolateral membrane (60). Calcium is then pumpcd out
of cells by the Ca2+-ATPase (PMCA 1b) at basolateral membranes. The Na-Ca exchanger
(NCXI) may also playa minor role in pumping out calcium from intestinal epithelial
cells (54). However, despite decades of research, the mechanisms explaining the activc,
transcellular route remain uncertain. This is shown by the fact that loss of either TRPV6
or Calbindin-D9k does not decrease intestinal calcium absorption, but loss of both TRPV6
and Calbindin-D9k does decrease the calcium absorption (6\).
Calcitriol is a critical stimulator of the active calcium absorption pathway in the intestine.
Calcitriol goes into the brush border cells to bind VDR, thus initiating downstream
transcription regulation (62). This process increases the expression ofTRPV6, Calbindin-
D9k PMCA Ib, and other proteins, thus causing calcium to be more efficiently absorbcd at
the small intestine (63, 64). IfVDRs are absent (so that calcitriol cannot act) or severe
Vitamin 0 deficiency is present (so that calcitriol is reduced or absent), intestinal calcium
absorption is significantly impaired, and hypocalcemia results. Calcitriol's role in
stimulating the active pathway is critical because dietary calcium intake is normally wcll
below the amount needed for the passive pathway to absorb the amount required.
As noted earlier, PTH indirectly regulates the active, transcellular transportation of
calcium by increasing Ia(OH)ase expression, leading to enhanced synthesis of calcitriol
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(65). Direct actions of PTI-[ to stimulate intestinal calcium absorption have been proposcd,
but have not been confirmed.
1.1.2.6 Calcitonin
Calcitonin was first purified by Copp and Cheney in 1962 (66, 67). Early experiments
showed that injection of commercial thyroid extract into dogs caused transient
hypocalcemia, and perfusion of blood containing high calcium into the thyroid and
parathyroid glands of dogs resulted in a systemic fall in blood calcium. These results
indicated that calcitonin was a hormone that lowered the blood calcium and was secreted
by thyroid gland (66, 67). Calcitonin was also thought to have the opposite actions of
PTH. Later studies showed that it is the C-cells of the thyroid gland that produce
calcitonin and not the cells that produce the thyroid hormone (68, 69). More recently, it
has been discovered that the brain, lactating breast, and placenta can also contribute to
calcitonin production to some extent. Within the C-cells at least, the CaSR responds to an
increase in serum calcium by stimulating the synthesis and release or calcitonin.
Calcitonin is a 32 amino acid peptide and expressed by the cl/cgrp gene located at human
chrolllosome II. An alternative splicing product orthe cl/cgrp gene is calcitonin gene
related peptide a (CGRP- a); it is produced by the nervous system and may not playa
significant role in calcium or bone metabolism. Calcitonin's actions to oppose PTI-I occur
in the kidney and osteoclasts. It can inhibit proximal tubular reabsorption of calciulll to
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increase urine calcium by effects on Na-H exchangers, and it directly inhibits osteoclasts
to decrease bone resorption (56, 70, 71).
Following Copp's initial discoveries, it became evident that the ability of calcitonin to
lower blood calcium was only seen with pharmacological dosages in humans. This Icd to
the historical view that calcitonin is physiologically unimportant in vivo (72). This
viewpoint was based on the fact that surgical removal of thyroid glands does not cause
hypocalcemia or any obvious bone phenotype (73-75). However, these experimcnts
overlooked more recently recognized calcitonin sources such as the breast and placcnta.
Increased calcitonin gene expression in lactating breast tissue elevates calcitonin in thc
serum of women who had a thyroidectomy (76). The surgical models of calcitonin
deficiency were not truly devoid of calcitonin, especially during pregnancy and lactation.
More recent studies using gene targeting techniques have shown that calcitonin may
function in mammals during reproductive periods. Previous studies in our lab showed thaI
calcitonin could protect bone from excessive resorption during lactation. Female c//cgrp
knockout mice do not make calcitonin. They lost twice as much BMC during lactation as
their normal sisters did, and treatment with exogenous calcitonin rescued the massive
bone resorption phenotype (77).
1.1.2.7 Calcitonin receptor
The calcitonin receptor (CTR) belongs to the 7-transmcmbrane and G-protein coupled
receptor family (78). CTRs are expressed at renal proximal tubules, osteoclasts in bone
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tissue, mammary tissue, placenta, and pituitary (78-81). Receptor modulating proteins
(RMPs) heterodimerize with CTR to create isoforms of CTR (82, 83). Scveral proteins
including CGRP-receptor component protein and receptor-activity-modifying proteins
(RAMPs) belong to RMPs (82).
I. I .3 Phosphorus homeostasis
Calcium and phosphorus metabolisms are interlinked since both are needed to mineralize
bone, and both are present in blood at concentrations that could cause damaging calcium-
phosphorus crystals to form. Phosphorus is abundant in vivo. Most of phosphorus is
storcd in bone with calcium in the form of hydroxyapatite crystals. The remainder largcly
exists in soft tissue, and less than 1% of phosphorus is in the ECF. There are two forms of
phosphorus in ECF: the organic form of phospholipids and the inorganic form of
phosphate (Pi). Pi homeostasis is critical in vivo, and any disorder of Pi homeostasis will
affect almost all organs. Maintenance of Pi homeostasis keeps phosphorus within a
narrow range of 2.4 - 4.1 mg/dL (84).
Several factors can affect Pi homeostasis. Under extreme conditions of phosphorus
deficiency, bone will break down to support the blood phosphorus level. In normal
conditions, the two pathways that regulate Pi homeostasis are intestinal absorption and
renal reabsorption. Intestinal absorption includes paracellular, passive absorption that
depends on diffusional flux and transcellular, active absorption that is calcitriol-
dependent and requires Na-P-binding protein (85, 86). Calcitriol stimulates thc activc
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absorption of phosphorus, however, the detailed mechanism needs further research (87).
On a normal diet, the phosphorus content usually exceeds daily needs such that passive
absorption is usually sufficient. Calcitriol's role to stimulate active absorption is normally
not essential.
The majority of renal excretion occurs at proximal tubules, and the rest of Pi is
reabsorbed at proximal straight tubules and distal tubules. Reabsorption at all three sites is
driven by specific phosphate channels called the Na-Phosphate cotransport system (NPT-
2) (88). PTH decreases the reabsorption of Pi by inhibiting NPT-2 expression and activity
at the 3 sites (89). This inhibition is thought to be related to the cAMP pathway induced
by activation of the PTHR.
Fibroblast growth [actor23 (FGF23) is a newly recognized and important factor
regulating Pi reabsorption in kidneys. It lowers the serum phosphorus by reducing renal
Pi reabsorption. This has been confirmed by human disorders and animals models, which
revealed that excess FGF23 action cause hypophosphatemia and renal phosphorus
wasting, whereas absence ofFGF23 leads to impaired renal phosphorus excretion and
hyperphosphatemia (90). FGF23 suppresses NPT-2 (91) and has negative effects on
calcitriol by inhibiting Iu(OH)ase activity (92). Reduced calcitriol contributes to renal
phosphate wasting and also leads to reduced Pi absorption at the small intestine. Binding
of FGF23 with its receptor in kidneys requires the existence of a co-factor called u-
Klotho (93). u-Klotho is also found in parathyroid cells where FGF23 appears to suppress
PTI-!.
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Both PTH and FGF23 play critical roles in phosphorus homeostasis since loss of either
leads to increased serum Pi level due to decreased urine Pi excretion.
1.1.4 Magnesium homeostasis
The human body is rich in magnesium (Mg). Sixty-six percent is located in bone, thirty-
three percent is intracellular and the remaining one percent exists in ECF including serum.
Of the Mg in serum, 30% is bound to protein and 70% is ionized. Magnesium can
suppress PTH release by acting on the CaSR, but it does not do so as effectively as
ionized calcium (27).
Mg homeostasis depends on the balance between intestinal absorption and renal handling.
Like Ca and Pi, Mg is absorbed by two pathways in the small intestine: a paracellular,
passive process driven by the Mg concentration in the intestinal lumen and an active
transcellular process mediated by transient receptor potential cation channel, subfamily M,
member 6 protein (TRPM6) (94). Calcitriol increases Mg absorption at the small intestine,
but whether PTH is involved in the process is still unclear (27, 95). The majority of Mg
reabsorption in the kidney occurs at the CTAL, with the remaining Mg reabsorbed at the
proximal tubule and OCT. TRPM6 is expressed in the OCT, suggesting a role in Mg
reabsorption at this site (94). PTH increases Mg reabsorption to some extent in the kidney,
but is not a physiologically important factor (96). The reabsorption can be suppressed
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partially by activation of the CaSR located at the proximal tubule, CTAL and OCT (97,
98).
1.2 Body adaptation during reproductive period
Reproduction involves unique adaptations to calcium and bonc metabolism in femalc
mammals. The reproductive period can be divided into thrcc phases: pregnancy, lactation
and recovery aftcr lactation. During pregnancy, the mother provides minerals for letaI
development mainly through increased efficiency of intcstinal absorption; during
lactation, the mother mobilizcs calcium from bone to provide to milk; after lactation, thc
maternal skeleton recovers from bone loss incurred during pregnancy and lactation. For
cach stage, the strategies used by the maternal body are diffcrcnt.
1.2.1 During pregnancy
The pregnant mammal adopts several strategies to maintain calcium homeostasis during
pregnancy. Intestinal absorption of calcium is dramatically increased (99). The ratc of this
intestinal absorption is elevated as early as 12 weeks into gcstation in humans and
remains at a high level throughout pregnancy (100). The dietary calcium intake of
pregnant women is often higher than prior to pregnancy if nutrition guidelines are
followed, and this may enhance the paracellular diffusion of calcium from intestinal
lumen to blood due to a high calcium electrochemical gradient in the lumen. Calcitriol
levels are 2 to 5 times higher during pregnancy, and this may explain increased
exprcssion ofTRPV6 and Calbindin-D9k at the intestinal cpithclial cells. The increascd
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TRPV6 and Calbindin-D9k induce more calcium absorbed by the transcellular, active way.
PTH related peptide (PTHrP) may also participate in the increased intestinal absorption of
calcium. It has structural similarity to PTH, enabling PTHrP to mimic PTI-I's actions on
the kidney to raise la(OH)ase expression and activity (101-103). Elevated la(OI-l)asc
catalyzes more calcitriol production, which in turn increases intestinal absorption. Other
factors such as high estradiol, prolactin, and placental lactogen have been shown to
stimulate la(OH)ase expression. It is also evident that high levels of calcit rioI may not
fully explain increased intestinal calcium absorption during pregnancy, since severely
vitamin D deficient rats and Vdr null mice each upregulate intestinal calcium absorption
to normal levels during pregnancy (104, 105). Prolactin, placentallactogcn and other
factors may stimulate intestinal calcium absorption through direct actions on entcrocytcs
(intestinal absorptive cells). Generally speaking, both paracellular and transcellular
calcium transportation contribute to the increased calcium absorption at the intestine.
The skeleton may also contribute calcium during pregnancy, but the extent to which this
happens in women is uncertain. Most studies have measured bone mineral content (BMC)
or bone mineral density (BMD) prior to pregnancy and 2 - 6 weeks after, with minimum
change to as much as a 4% decrease observed. The concern about fetal radiation exposurc
limits such experimental data. Animal studies have shown that the skeletal response to
pregnancy depends partially on genetic background. Outbred Blackswiss mice gained
BMC by nearly 20% in the whole body and spine during pregnancy, suggesting that the
mother stores bone minerals, mainly calcium, to prepare for massive bone calcium loss
during lactation due to milk production (77). Conversely, our lab has also found that
20
inbred C57BL/61 mice gain BMC at the whole body level but lose 10-15% at thc spine
during pregnancy. The Wysolmerski lab has found that inbred COl mice have no change
in BMD during pregnancy (106).
The increased intestinal absorption of calcium leads to an increased renal filtered load of
calcium and increased urine calcium excretion (99). This may also indicate that females
(both humans and other mammals) take in more calcium than nceded during pregnancy,
with the kidneys excreting the excess.
1.2.2 During lactation
1\t pregnancy, the calcium balance may be neutral or slightly negative; during lactation, a
net loss of calcium occurs to provide sufficient calcium for milk production. The daily
calcium loss in women normally ranges from 280 to 400 mg, sometimes reaching 1000
mg (99). [n order to maintain maternal calcium homeostasis during lactation, different
physiological strategies are employed during pregnancy.
Unlike a possible modest increase in bone metabolism during pregnancy, bone resorption
is markedly increased during lactation in order to provide the needed calcium for milk
(99). This leads to a net bone loss of 5 - 10% over 3 - 6 months in humans and 25 - 30%
over 3 weeks in normal rodents. As discussed earlier, PTI-I stimulates osteoclast-mediated
bone resorption, but PTI-I normally becomes suppressed during lactation and does not
drive bone resorption. Even without PTI-I, women and rodents lactate normally (107). The
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circulating PTHrP concentration goes up during lactation and appears to be produced by
mammary tissues, where tissue and milk levels of PTHrP are 1,000 - 100,000 timcs
greatcr in concentration than in blood (108). Supporting evidencc that PTHrP is needed
for bone resorption during lactation includes the fact that a conditional knockout of
PTHrP from mammary tissue at the onset of lactation causes less bone to be resorbcd
(108). In addition, human studies of hypoparathyroidism show that calcium and bonc
mctabolism returns to normal during lactation. PTHrP is likely acting on the PTHR at thc
surface of osteoblasts to increase osteoclast differentiation by RANKLIRANKJOPG
pathway. Also during lactation, estrogen is inhibited by prolactin and by direct actions of
suckling to inhibit GnRH. Low estrogen is known to increase bone resorption by
increasing the ratio ofRANKL to OPG. Thus during lactation, the effects of low estrogcn
and high PTHrP combine to stimulate more bone resorption than either alonc should
Some studies have found that PTH may not be suppressed during lactation in humans,
rats and certain strains of mice. This has been reported in women from Asia and Africa
who have habitually low intakes of calcium or high intakes ofphytate, which blocks
intestinal calcium absorption (109). In rodents, a high litter size ora low calcium intake
will induce a compensatory rise in PTH. And so in rodents both PTHrP and PTH may bc
nccded to ensure that sufficient calcium is provided to meet the needs of the suckling
pups without causing hypocalcemia in the mother.
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The kidneys also participate in the maintenance of the maternal calcium supply during
lactation. Calcium is actively reabsorbed such that the urine calcium falls to low levels.
Since PTI-I is normally low during lactation, PTI-IrP is likely enhances tubular calcium
reabsorption by mimicking the renal actions ofPTI-I (110, III).
Quite different from the increased intestinal calcium absorption during pregnancy,
intestinal calcium absorption decreases during lactation to non-pregnant levels in humans
(112,113). Even though maternal calcium intake may be increased during this period,
there is no difference in the rate of calcium absorption between lactating and non-
pregnant women. This change may be in response to the fall of calcitriol to normal levels
during lactation as well as the reversal of estrogen and placental lactogen levels (114,
115). In contrast to humans, rats maintain an increased calcitriollevel during lactation
and increased intestinal calcium absorption (116). Relative low body weight and large
litter size (high demand for milk) may make rats develop this adaptation to support
calcium homeostasis during lactation. Mice appear to similarly have elevated calcitriol
and likely increased intestinal calcium absorption during pregnancy (105).
1.2.3 During recovery after lactation
The bone loss resulting from lactation is fully and quickly reversed afterwards with
recovery of BMC back to the pre-pregnant level or higher (77, 107, 117). The recovery
process usually takes 6 - 12 months and 10 - 20 days in humans and mice, respectively.
So far the mechanisms underlying post-weaning recovery are still unclear. Understanding
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these mechanisms will not only increase our knowledge of human physiology but may
also provide novel ways of stimulating bone formation to treat osteoporosis.
Up to now our lab has confirmed that loss ofPTI-I, VDR, calcitonin, or osteoblast-derived
PTl-IrP has no effect on bone recovery after lactation (104, 118). Estrodiol levels are
suppressed during lactation and return to normal afterward, and this might stimulate bone
recovery. However, estradiol is not a potent stimulator of osteoblast functions, and
experimental evidence in humans and rodents suggests that estradiol is not responsible for
rapid bone recovery after weaning. Further research to understand the mechanism
underlying post-weaning recovery is needed.
1.3 Animal model: CTR gene (Clr) heterozygous mice
This study uses mice in which the gene encoding the CTR (Clr) has been ablated. Clr
heterozygous mice are maintained on the C57BLl6J inbred strain (C57), which is widely
used in laboratory research. Clr is located at chromosome 6 in C57 mice. Exon 6 and
Exon 7 of Clr were ablated by insertion of neomycin to block all isoforms of CTR in
C57/BL6J mice, thus blocking the Clr expression. Three genotypes result from mating
heterozygous males and females together: wildtype with both normal Clr alleles,
heterozygous (J--IET or Clr+I-) with one normal Clr allele and one Clr allele knocked out,
and null with both Clr alleles knocked out (CII·-I-). Unfortunately, most Clr null mice die
mid-gestation due to unknown reasons, and very few studies have been done on them
(119). A few null mice have survived in our laboratory, but velY infrequently.
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Heterozygous mice (C/J·+I-) have been studied as adults. They are phenotypically normal,
fcrtile, and have normal life spans. Or expression was found to be decreased by twofold
in osteoclasts obtained from Or+l- mice (19). C57 Or+l- mice have also been found to
have increased bone mass due to promoted bone formation (19), but the mechanism by
which partial loss of calcitonin's actions would lead to increased bone mass is unknown.
1.4 Project description
Previous studies in our lab havc shown that calcitonin protects against excessive bonc
resorption during lactation since calcitonin null mice (Cr
'
-) lost twice as much bonc as
WT sisters (77). CTR is known to be expressed by osteoclasts, mammary tissue, and
pituitary. However, we do not know which of these three CTR sites are required for
calcitonin's actions during lactation: in bone, calcitonin directly suppresses osteoclast-
mediated resorption; in mammary tissue, it may playa role in regulating calcium
pumping or PTHrP expression, since in its absence both milk calcium and PTHrP
expression increased; in the pituitary gland, calcitonin appcars to suppress prolactin, and
so its absence during lactation could induce higher prolactin levels, which would cause
both more profound estrogen deficiency and greater stimulation of PTHrP expression.
The original purpose of my project was to determinc whcther global loss of Or leads to
the same phenotype as loss of calcitonin. If so, this would enable more targeted studics to
address which tissue (osteoclasts at bone tissue, mammary tissue, or pituitary) and
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through which mechanisms the calcitonin-CTR interaction regulates calcium and bone
metabolism during lactation; however, due to most Or null mice dying in utero, I have
had to use Or+l - mice instead. Since previous investigators showed Or to be down
regulated 2-fold in Or+l- mice, this model seemed appropriate to study as a
haploinsufficient model ofCTR signaling. In this project, the BMC phenotype was
determined first in both C57 WT and 0,.+1- mice throughout the reproductive cycle, and
then the potential factors contributing to it were investigated.
26
2 Materials and methods
2.1 Animal husbandry
('".+1- mice maintained in the C57 background were kindly provided by Dr. Galson
(Department of Medicine, University of Pittsburg, Pittsburgh, PA, USA). They werc
raised on a regular laboratory mouse diet (1% calcium, 0.75% phosphorus, 22% protcin,
5% fat) and maintained in the Animal Care Facility at Memorial University of
Ncwfoundland. The animal holding room is set on a light timer of on at 8 a.m. and of/at 8
p.m. for a total of 12 hours of light and 12 hours of dark per 24 hours. Both femalc and
male mice were weaned when three weeks (wk) old. Male and female mice were
separated into different cages with a maximum of four mice per cage. After 10 wk of agc,
when mice reach a plateau in bone mass and are sexually mature, one pair of virgin
female mice (one WT, one 0,.+1-) within the same litter was randomly selected to mate
with the same male mouse from a different mother. The next morning, the male and
female mice were separated and the female mice were checked for a mucus plug, which
indicates that mating has occurred. Female mice with mucus plugs were put into scparatc
cages, and the day was marked as Day 0.5 of pregnancy. Pregnancy proceeded normally,
and the pups were allowed to be born and nursed normally. At Day 21 of lactation, pups
were manually weaned from their mother. To exclude the possibility that the number of
pups could affect the BMC phenotype ofWT and 0,.+1- mice, litter size was recordcd. No
lillers were included where the mother had less than 5 or more than 10 pups. All mouse
experiments were approved by the Institutional Animal Care Committee of Memorial
University of Newfoundland.
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Thc reproductive cycles ofWT and 0,.+1- mice were consistent. After 7 - 10 days (d) of
pre-pregnancy baseline, a full reproductive cycle lasted about 61 d. This included
gestation of 19 d, lactation of21 d, and 3 wk of recovery after lactation. At the end of
lactation, the litter size of experimental dams was recorded.
2.2 Experimental time points and design
All cxperiments involved comparisons between 0,.+1- and WT mice at the following timc
points. During a 7 - 10 d interval after 10 wk of age and before mating, experimcntal
samples were collected twice and marked as baseline I and baseline 2. Gestation lastcd
19 d, and so at Day 18.5 of pregnancy, experimental samples were collected and markcd
as late pregnancy. The day when pups were delivered was considered Day I of lactation.
Experimental samples collected at Day 7 of lactation were marked early lactation, and
those collected at Day 21 of lactation were marked late lactation. After weaning (Day 21
of lactation), samples were collected at weekly intervals (the end of each recovery week)
and marked recovery I, recovery 2, and recovery 3, respectively. A brief description of
experimental samples collected at each time point, and the application of those samples,
are shown in Figure 2. Detailed experimental proccdure is described in the following
sections.
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WTmice
!
Ctr-i-mice
• BMC measurement
(Basdinc I,Basclinc2, Lah.: Pregnancy, Lttt.: Lactation and Rccuvery l,2and3)
{
• Boneformationandresorption
• Urine and serum collection marker tests
• PTII assay
• Calcium,phosphorusand
magnesium assays
(Basc!incl,Basclinc2.LatcPrcgnancy,EcarlyLactation,LatcLaclationandRccoycryl.2
and 3)
• MilkcolJection
(EcarlyLuctatiun)
• BonetissuecolJection
(Basclincand Late Lac1<ttiun)
{ • Calcium assay
{
• Micro-computedtomograpby
• Biomecbanicaltests
• CtrmRl'iAexpressionanalysis
Figure 2: Experimental design. Experiments in my master's project arc briefly
described here. The time points of samples collected for each experiment arc shown in
parentheses.
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2.3 Genotyping
Polymerase chain reaction (PCR) was carried out to determine the genotype of pups from
HET x HET mating. The whole process included tagging and tailing, Deoxyribonucleic
Acid (DNA) extraction, PCR, and gel electrophoresis.
2.3.1 Tagging and tailing
Mice were briefly anaesthetized with isoflurane. During the 10- 15 seconds (s) of
unconsciousness, an ear tag with a unique number was applied to the right ear. Right arter
the tagging, 1 cm of tail was cut by sterile razor blade and put into a sterile micro-
centrifuge tube containing 0.5 mllysis buffer [100 mM Tris HCL, pH 8.0; 500 mM
ethylenediaminetetraacetic acid (EDTA), pH 8.0; 0.2% sodium dodecyl sulfate (SDS);
200 mM sodium chloride (NaCt); 100 ~g/ml proteinase K (Invitrogen)]. The tails were
digested at 55°C overnight.
2.3.2 DNA extraction
The morning after tagging and tailing, micro-centrifuge tubes containing digested tails
were shaken by hand for 2 to 3 min, and then spun on a centrifuge (lEC Micromax) for 10
min at 15,000 revolutions per minute (rpm) to precipitate hair. The supernatant was
poured into fresh tubes containing 0.5 ml isopropanol (J-lPLC grade, Fisher Scientific)
and then tubes were inverted to precipitate DNA. The DNA pellet was physically pickcd
out with small pipette tips and put into a fresh eppendorftubes containing 0.5 ml water.
The tubes were shaken by hand for 5 min to dissolve DNA into a viscous solution. In the
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fumehood, 0.5 ml well-mixed phenol/chloroform/isoamyl alcohol (25:24:1) (Fisher
Scientific) at 4°C was added to the tubes. The tubes were shaken by hand for 1 min until
the solution became turbid and milky, and then tubes were centrifuged for 2 min at
15,000 rpm. [n the fumehood, the supernatant of each tube was carefully pi petted oil and
placcd in a fresh eppendorftube. One m1 of Ethanol sodium acetate (EtOH:NaOAc)
(25: 1) solution at -20°C was added to the supernatant. Tubes were inverted several times
until DNA came out of the solution. Tubes were centrifuged for 10 min at 15,000 rpm.
The supernatant was discarded and 1 ml 70% EtOI-l was added to wash the DNA pellet.
Tubes were spun for 10 min at 15,000 rpm. EtOH was poured off and the rcst was
pi petted off. The DNA pellet was air dried for 2 h and then resuspended with 50 ilL TE
buffer (10 mM Tris, 1 mM EDTA, pH 8.0). The DNA sample was stored at 4°C until
further use.
2.3.3 PCR
PCR was carried out on the DNA collected from mice tails. In order to distinguish Or+l-
from WT mice, a 4-primer system was used, including one pair for Or and one pair for
neomycin cassette (Neo). Primer sequences are as follows: Or-Forward: 5'- CAG CCT
GTA AGC TTT CAG CCA -3', Or-Reverse: 5'- ATT crr ATC CAA TAC AGA GAT
T -3', Product = 229 bp; Neo-Forward: 5'- ATG CCG CCG TGT TCC -3', Nco-Reverse:
5'- GCC CCT GAT GCT CTT CGT -3', Product = 400 bp.
Each PCR mix (49 ~lL) was made with the following ingredients: 1x PCR Run Buffer
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(20mM Tris-HCI, 50 mM Potassium chloride (KCI)) (Invitrogen), Deoxyribonucleotide
triphosphates (d TPs) (0.2 mM Deoxyadenosine-5'-triphosphate (dATP) : 0.2 mM
Deoxythymidine triphosphate (dlTP) : 0.2 mM Deoxycytidine triphosphate (dCTP) 0.2
mM Deoxyguanosine triphosphate (dGTP): H20 = I : I : I : I : I) (Invitrogen), 0.4 mM
primers (Or-Forward, Or-Reverse, Neo-Forward, Neo-Reverse), 50mM MgCI2, I U Taq
DNA Polymerase (0.02 U/ ~lL) (Invitrogen) and deionized water. 1.5 ilL of DNA sample
was added into the solution in each PCR tube. PCR tubes were put on Peltier Thermal
Cycler-Dual Alpha Blocks (PT-200 DNA Engine Thermal Cycler) for reactions.
The PCR cycling program was as follows: Step I: 94°C for 2 minutes for initial
denaturation; Step 2: 94 °c for 40 seconds for denaturation; Step 3: 54°C for 30 seconds
for annealing; Step 4: 72 °c for 40 seconds for extension; Step 5: back to Step 2 and
repeat 35 times; and Step 6: 4 °c indefinitely.
2.3.4 Gel electrophoresis
Horizontal gel electrophoresis was used to separate and display the PCR products. The
gel was made with the following ingredients: 10 ml lOx Tris-acetate-EDTA buffer (0.12
M EDTA, 0.40 M Tris, 11.5% Glacial Acetic Acid, pH 8.0),90 ml deionized water, 1.2%
agarose (1.2 g) (Invitrogen) and I0 ~lL SYBR Safe DNA Gel Stain (Invitrogen). Agarosc
powder was added into the TAE buffer solution and then dissolved in the microwave (2
min). SYBR gel stain was added to the solution, and all the ingredients were well mixed.
The solution was poured into the gel mold and allowed to solidify. The gel running buffer
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was made as follows: 70 ml lOx TAE buffer was diluted by 630 ml deionized watcr to
prepare I x TAE working buffer.
Orange G (Sigma, United States) was used as gel loading dye. It was made with 100 ml
lOx TAE, 500 mg Orange G, and 50 ml 100% Glycerol. 2 ilL of Orange G was added to
the PCR product and mixed well. IS ~lL of PCR product and the loading dye mix was
injected into each well of the gel. 200 V was applied across the gel in running buffer for
20 min.
The gel was imaged under UV excitation with digital photography (Gel Logic 100,
Mandel). The results were read using Kodak MI software. A single 229 bp band of Or
indicated WT mice, a single 400 bp band ofNeo cassette indicated null mice, and both
229 bp and 400 bp bands of Or and Neo cassette indicated heterozygous (Or+1o) mice.
2.4 BMC measurement
BMC was measured by Lunar Piximus2 dual-energy X-ray (OXA) bone densitometer
(General Electric) to investigate BMC pattern changes during the reproductive period of
both Or+1o and WT mice. The densitometer was calibrated using a Phantom with 11.9%
fat and 0.063 g/cm2 BMO each day. The deviation of both fat and BMO for quality
control was < 2%. The BMC value of each experimental mousc was measured at baseline
I, baseline 2, late pregnancy, late lactation, and recovery 1,2, and 3. Prior to the OXA
scanning, mice were anaesthetized by an i.p. injection of 40 ilL of 83.3 mg/ml Ketamine
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and 3.3 mg/ml Xylazine. The anaesthetized mice were placed onto the holding trays and
then put into the scanning window on the densitometer for whole body scanning. Aftcr
the scanning was completed, dams were laid in a warm place until awake and then wcrc
returned to pups. The scan image was adjusted to exclude the head. The main value
obtained was whole body BMC (excluding the head). The BMC values of the lumbar
spine (Ll-L6) and left tibia were calculated from the whole body scanning results of the
software, which enabled these regions of interest to be highlighted. In addition to
analyzing the absolute value of BMC, the values obtained during the reproductive cycle
of each mouse were expressed as a percentage change from the pre-pregnancy baselinc
value.
2.5 Urine and serum collection
Urine and serum were collected at baseline I, baseline 2, late pregnancy, early lactation,
late lactation and recovery 1,2, and 3. Experimental mice were placed in clean cages
containing one mouse each. The mice normally void promptly. Urine was immediately
collected into small sterile centrifuge tubes by pipette and stored in the freezer at -20°C.
Serum collection was conducted after each BMC measurement while the mice were still
anesthetized. The end of the mouse tails was cut using a sterile razor blade. Blood was
collected into small centrifuge tube while applying light pressure on the tail. The
collected blood was placed at room temperature for at least hal f an hour and then
centrifuged for 8-9 minutes at 14,000 rpm. Serum was separated as the top layer
(supernatant liquid) from the whole blood. Serum was stored at -20°C.
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2.6 Milk collection
Milk was collected from experimental dams at early lactation for milk protein and
calcium analyses. Pups were separated from mothers 1 h before milk collection. The
dams were injected (i.p.) with 40 ilL of83.3 mg/m! Ketamine and 3.3 mg/ml Xylazinc,
and I IU of Oxytocin (100 ilL of solution). Oxytocin stimulates milk let down and
ejection. When the mice were under anesthesia, mice were placed supine (abdomen with
an upward exposure), and hair was pushed down to expose the nipples. The mammary
gland was squeezed from the root to the top by hand, and capillary tubes were used to
collect milk coming out from the nipples. An average of60 ~lL of milk could be collected
from one mouse. The collected milk was transferred from capillary tubes to plastic
centrifuge tubes and stored at-20 DC.
2.7 Bone tissue collection
Bone tissues, including forelimbs, lumbar spines, and tibias, were collected from all mice.
Tibias were collected at pre-pregnancy baseline for Or expression analysis. Lumbar
spines and tibias were collected at late lactation for micro-computed tomography and
biomechanical tests. Mice were euthanized by cervical dislocation. Tibias for Or
expression analysis were harvested immediately. Once flesh attached to the tibias was
removed by forceps, the tibias were snap-frozen in liquid nitrogen and then stored at -80
°C freezer. Lumbar spines (L I - L6) and tibias for biomechanical tests were harvested by
the same methods, but stored at -20°C.
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2.8 Serum and urine total calcium measurement
The total calcium assay is based on the principle that Arsenazo III reacts with calcium to
form Arsenazo III-calcium complex, which displays blue-purple color. The color has
maximal absorbance at a wavelength of 650 nm and is directly proportional to the
concentration of total calcium. Serum and urine samples at baseline (pooled by basel inc I
and baseline 2 samples), late pregnancy, late lactation and recovery 1,2, and 3 were
tested. Prior to the measurement, urine was diluted in saline by a factor of 10. Samplcs
were measured in duplicate according to the procedure in the kit (Genzyme Diagnostics,
Reference Number: 140-20). The absorbance was read at 650 nm in a spectrophotometcr
(Ultrospec 2000, Pharmacia Biotech). The final results of urine total calcium were
cxpressed as urine total calcium concentrations normalized to urine creatinine
concentrations (mmol Ca/mmol Creatinine). Deionized water was used as a blank.
2.9 Serum and urine inorganic phosphorus measurement
This assay was based on the principle that inorganic phosphorus reacts with ammonium
molybdate in the presence of sulfuric acid to produce unreduced phosphomolybdate
complex. The increase in absorbance at a wavelength 01'340 nm is directly proportional
to the concentration of inorganic phosphorus in the samples. Serum and urine samples at
baseline (pooled by baseline I and baseline 2 samples), late pregnancy, late lactation and
recovery 1,2, and 3 were measured. Prior to the assay, urine was diluted in saline by a
factor of 10. Experiments followed the instructions in the kit (Genzyme Diagnostics P.E.1.
Inc., Catalogue number: 117-10) in duplicate. The absorbance was read in a
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spectrophotometer (Ultrospec 2000, Pharmacia Biotech) at 340 nm. The final results or
urine phosphorus were expressed as phosphorus concentrations normalized to urine
creatinine concentrations (mmol P/mmol creatinine). Deionizcd water was used as a
blank.
2.10 Serum and urine magnesium measurement
Serum and urine magnesium concentrations were tested. This assay was based on the
principle that xylidyl blue-I reacts with ionized magnesium to form Mg-xylidyl bluc
complex (red). The increase in the absorbance at 520 nm wavelength is directly
proportional to the concentration of magnesium in the samples as a result of the red
complex formed. Serum and urine samples at baseline (pooled by baseline I and basclinc
2 samples), late pregnancy, late lactation and recovery 1,2, and 3 were tested. Prior to thc
assay, urine samples were diluted in saline by a factor of 10. Expcriments were conductcd
in duplicate according to the procedure in the kit (Diagnostic Chemicals Limited,
Catalogue number: 125-12). Absorbance was measured at 520 nm in a spectrophotomctcr
(Ultrospec 2000, Pharmacia Biotech). The final results of urine magnesium were
normalized to urine creatinine concentrations (mmol Mg/mmol creatinine). Deionized
water was used as a blank.
2.11 Urine creatinine measurement
Creatinine was measured to normalize the values of all urinary metabolites. The assay
was based on the principle that in an alkaline environment, creatinine reacts with alkalinc
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picrate to produce creatinine-picrate Janousky complex. The amount of increase in
absorbance at a wavelength of 51 0 nm is directly proportional to the concentration of
creatinine in the sample. Urine samples at Baseline (pooled by basel inc I and basel inc 2
samples), late pregnancy, early lactation, late lactation and recovery 1,2, and 3 were
tested. A dilution factor of 10 was used. Experiments followed the procedure in the kit
(Diagnostic Chemicals Limited, Catalogue number: 221-30) in duplicate. The rcsults
(mmol) were read at 510 nm in a spectrophotometer (Ultrospec 2000, Pharmacia
Biotech). Deionized water was used as a blank.
2.12 Serum procollagen type IN-terminal propeptide (P INP) assay
PINP is a bone formation marker. The synthesis of type I collagen, which is the major
organic component in bone matrix, is an essential step in bone formation. During
formation of the collagen, propeptides are derived from both N- and C-terminal cnds of
the procollagen molecule. These propeptides are released into the circulation, making thc
detection of such propeptides available through enzyme immunoassay (EIA). Thereforc,
the concentration ofPINP in serum can reflect the activity of bone formation. A PI P kit
(Immunodiagnostic Systems Holdings pic, Reference number: AC-33FI) applies
competitive EIA methodology using a polyclonal rabbit anti-PINP antibody. Serum
samples at baseline (pooled by baseline I and baseline 2 samples), late pregnancy, late
lactation and recovery I, 2, and 3 were measured. Experiments were carried out according
to thc methods described in the kit in duplicate. Results wcre read at 450 nm (reference
650 nm) in a microplate reader (Model 3550, Bio-Rad).
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2.13 Urine deoxypyridinoline (01'0) assay
01'0 is a bone resorption marker. Type I collagen in bone matrix is crosslinked by
pyridinoline (PYO) and 01'0, both of which can provide rigidity and strength. 01'0 is
derived from the enzymatic reaction of Iysyl oxidase on the amino acid lysine. OPO is
released from bone matrix into the circulation while bone is resorbed and excreted into
urine without any effect from the diet. The process makes 01'0 detection available by
EIA. Therefore, the 01'0 concentration in urine can reflect the extent of bone resorption
in vivo. Urine samples at baseline (pooled by baseline I and baseline 2 samples), latc
pregnancy, early lactation, late lactation and recovery I were compared. 01'0 EIA kit
(MicroVue Quidel, Reference number: 8007) is a competitive EIA utilizing monoclonal
anti-OPO antibody that was used by duplicate according to manufacture's instructions.
Results were read at 405 nm in a microplate reader (Model 3550, Bio-Rad). The final
results were expressed as 01'0 concentrations normalized to urine creatinine
concentrations (mmol OPO/mmol Creatinine).
2.14 Serum PTI-I assay
PTII plays an essential role in maintaining calcium homeostasis in vivo. A PTI-! kit
(Immutopics, Catalogue number: 60-2300) is specific for the intact 84 amino acids of"
PTI-I. It applies two-site enzyme-linked immunosorbent assay (ELISA) methodology to
determine serum PTI-! concentration. PTI-I is captured by anti-mouse PTI-I antibody
(second antibody) anchored at the surface of the well. Biotin-horseradish peroxidasc
(J-1RP) system is used to detect the concentration ofPTH by using I-IRP-Iabelcd anti-
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mouse PTH antibody (first antibody). Serum samples at baseline (pooled by baseline I
and baseline 2 samples), late pregnancy, late lactation, and recovery I were used to detcct
PTH concentration during reproductive period. Experiments followed the procedure in
thc kit in duplicate. Results were read at 450 nm in a microplatc reader (Model 3550, Bio-
Rad).
2.15 Milk protein measurement
Since much of the calcium in milk is bound to milk proteins, the protein level in milk was
assayed to normalize milk calcium concentration. The principle of milk protein
measurement was based on the biuret reaction: Cu2+ is reduced to Cu l+ by protein in an
alkaline medium, forming Cu 1+-protein complex, and the Cu 1+ level can be
colorimetrically detected by using bicinchoninic acid. The absorbance ofCu
'
+ in thc
complex is directly proportional to protein content (20-2000l-lg/ml) at 562 nm
wavelength. Milk collected at early lactation was used, and the measurement followed thc
proccdure in the kit (Pierce BCA Protein Assay Kit, Thermo Scientific) by triplicate.
Results were read at 562nm in a microplate reader (Polarstar Optima, BMG).
2.16 Milk calcium measurement
Milk calcium content was measured by flame atomic absorption spectroscopy (Perkin-
Elmer 2380 Atomic Absorption Spectrometer). The principle is that electrons of calcium
atoms are promoted to a higher orbit by the flame, thus absorbing radiation of calcium-
specific wavelength. By comparing radiation flux without and with calcium-containing
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samples, calcium concentration is calculated based on Beer-Lambert Law by a calculator
in the machine. Milk was brought to room temperature and then diluted by a dilution
factor of200 (5 flL milk in 995 flL nitric acid). Low (2.5 flg/ml), medium (7.5 ~lg/ml),
and high (15 flg/ml) calcium standards were made by calcium reference standard solution
(Fisher Scientific) and nitric acid. Measurement of standards and milk samples followed
the manual of the atomic absorption spectrometer. Milk samples were tested in triplicatc.
2.17 Micro-computed tomography (flCT)
rrozen lumbar spines were fixed in formalin buffer and scnt to the Centre for Bone and
Periodontal Research at McGill University for ~lCT. It was performed using a high
resolution flCT scanner (SkyScan-1 072, Aartselaar, Belgium). The largest lumbar
vertebrae in each sample tube were selected for analysis. The vertebrae were wrappcd
with Parafilm to prevent dehydration and then scanned at a source power of 45 kY/222
~lA and spatial resolution of 5.63 Ilrn/pixel. The rotation was set at 0.9 degrees/step for
180 degrees and the exposure time was set at 2.8 seconds/step. Images wcre taken by X-
Ray CCO-camera based on a cooled 12-bit CCO-sensor of I 024x I 024 pixcls. 20 cross-
section images from ~lCT scans were used to construct and calculate the 30 architcctural
parameters for the trabecular bones in the lumbar including mean trabecular thickncss,
mcan trabecular spacing, total volume, anisotropy, volume fraction (%), volume (mm\
surface (mm2),surface/volume (%) and structure model index.
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2.18 Biomechanicaltests
2.18.1 3-point bend test
3-point bend (3PB) tests were carried out to measure the differences of cortical bone
strength between WT and Ctr+l- mice throughout the reproductive cycle. Tibias for 3PB
tests were collected from WT and Ctr+l- mice at both baseline and late lactation. They
were put into PBS and then thawed at room temperature for at least 2 h prior to analysis.
The tests were performed by a single-column Tnstron Series 3340 electromechanical tcst
instrument (instron, Norwood, MA, USA) together with the Tnstron Series IX/s softwarc
package. Tibias with the same length were carefully placed on the platform with each end
fixed. A load cell of ION was set 1cm above the tibia midshaft. Once the analysis bcgan,
the cross-head of the load cell descended at 10mm/minute until the tibia was brokcn.
Parameters including maximum load, displacement (Ilm), maximum strain (gf/mm\
maximum strain (%), and slope (gf/mm) were recorded and displayed by the software.
2.18.2 Reference point indentation test
The reference point indentation (RPI) test is an alternative method of detecting cortical
bone strength. The principle is that the test probe, which is shielded by the outer reference
probe from surrounding soft tissues, hits the bone surface to make a displacement relative
to the reference point set by the outer reference probe. The value of the displacement
[Indentation distance increase (Ilm)] is used as an indicator of cortical bone strength. The
bone surface isn't permanently deformed by this procedure. Tibias and vertebrae fi'om
WT at baseline stage and late lactation stage were sent to Active Life Scientific, Inc.
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(Santa Barbara, CA, USA) for the RPI test. Unfortunately the company declined to test
the Clr+l - samples as well, saying that they could only do proof-of-principle tests on the
WT samples and not a collaborative analysis of WT vs. Clr+l - samples.
2.19 Clr gene expression analysis
Clr expression at bone tissue was tested to determine the effect of haploinsufficiency on
CIJ·+1- mice. The whole process included ribonucleic acid extraction, cDNA synthesis and
real-time quantitative RT-PCR.
2.19.1 RNA extraction
Total RNA was extracted from both left and right tibias of female micc using the RNeasy
Midi Kit (Qiagen). Experimental steps followed the protocol in the kit. After extraction,
RNA concentration and quality were measured on the 2100 Bioanalyzer platform
(AgilentTechnologies).
2.19.2 cDNA synthesis
Two ~lg of mouse tibia RNA samples were used for cDNA synthesis by Superscripllll
First-strand Synthesis System (Invitrogen). The experimental procedure followed the
protocol in the kit. The synthesis program was as follows: Step 1: 25°C for 10 min; Step
2: 37 °C for 2 h; Step 3: 85°C for 5 min; Step 4: 4 °C indefinitely.
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2.19.3 Real-time quantitative RT-PCR
Real-time quantitative RT-PCR was conducted using Taqman® Universal PCR Mastcr
Mix (Applied Biosystems) on the YiiA™ Real-time PCR System (Applied Biosystems).
A minor groove binder (MGB) probe with a Fluorescent reporter dye 6-
carboxylfluoresceine (FAM) rep0I1er dye at the 5' end and a non-fluorescent quenchcr at
thc 3' end were used in the assay. When targeted cD A was amplified, the MGB probe
was digested by DNA polymerase and the FAM reporter dye was released. Fluoresccnce
from free FAM reporter dye was detected by the real-time PCR system. The intensity of
Iluorescence was directed to the concentration of targeted cDNA within proper rangc. Clr
primers were pre-designed by Applied Biosystems (Mm00432271_ml). The experiment
followcd the protocol in the kit. All samples were tested in triplicate and threshold cycle
valuc was used as indicator of gene expression. GAPDH was used as endogenous control.
Thc rcal-time quantitative running program was as follows: Step I: 50°C for 2 min for
Uracil-N-glycosylase (UNG) incubation; Step 2: 95°C for 20 s for polymerase activation;
Step 3: 95°C for I s to denature; Step 4: 60°C for 20 s for annealing; Step 5: Back to
stcp 3 and repeat 40 times.
2.20 Statistical analysis
SYSTAT 5.2.1 for Macintosh (SYSTAT Inc, Evanston, IL, USA) was used for data
analysis. Significant differenccs among means wcre calculated by analysis ofvariancc
(ANOYA), and Tukey's test was carried out to determine which pair(s) of mean(s) was
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(were) significantly different. Real-time RT-PCR results werc analyzed by a T MC T
method. All experimental results were expressed as the form of mean ± standard error
(SE). Any significant differences were marked in the graphs. The number of samples
studied was indicated in parentheses in the graphs.
According to previous studies in our lab, the minimum sample size for each group to find
significant differences is 5 mice for BMC measurement. P1NP, OPO, PTI-I, and serum
and urine mineral assays require at least 5 samples of each group. Collaborators havc
advised that the 3-point bend tcst needs 15 samples of each group for the most reliability,
but such a high number of samples were not practical for this study.
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3 Results
3.1 Genotyping
In order to distinguish CII·+1- and WT female mice, DNA samples were extracted from the
tails to genotype by PCR. Consistent with previous studies, no CTR null mice were
observed from C57 HET x I-IET mating due to their death in mid-gestation. Thus, in the
following experiments, [ compared WT mice to Clr+l- mice. An example of genotyping
results is shown in Figure 3.
3.2 Litter size
WT and Clr+l- mice had the same mean litter size, with 8 ± 0 in WT and 8 ± 1 in CII·+1-
respectively. Results are shown in Figure 4.
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400 bp
300 bp
200 bp
75 bp
400 bp
229bp
Marker WT WT O,.+!- 0,.+/- Blank
Control
Figure 3: Example of genotyping results. A single band at 229bp indicated the
genotype as WT, while bands at both 229 bp and 400bp indicated the genotype as 0,.+1-.
A single band at 400 bp would indicate a null mouse, but none were found during the
whole project. A blank Control was used in PCR.
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Figure 4: Litter sizes in WT and Ctr+l- mice at Late Lactation. The numbers of pups in
both WT and Or+l- mice were counted at Late Lactation. No significant difference of
litter size was found between WT and Or+l- female mice.
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3.3 BMC measurement
At pre-pregnancy baseline stage, the BMC ofWT and 0,.+1- mice was not different (0.501
± 0.021 and 0.520 ± 0.0 18, respectively) (Figure 5).
Relative changes of whole body BMC (largely cortical bone) of both WT and 0,.+1- micc
throughout the reproductivc period are shown in Figure 6. Both genotypes gained a
similar percentage of bone relative to baseline during pregnancy (7.4 % ± 3.4 % in WT
and 7.7 % ± 3.9 % in 0,.+1-). During lactation, WT and 0,.+1- mice each lost about 18% of
BMC, falling to -10.7 % ± 3.4 % BMC and -10.6 % ± 2.0 % BMC relative to baselinc,
respectively, and these values were significantly different from late pregnancy (p < 0.01).
After weaning, both groups recovered to a mean value above Baseline, achieving a 4.6 %
± 3.8 % increase in WT and 2.9 % ± 3.1 % increase in 0,.+1-, but these were not
significantly different from baseline. 0 significantly different changes in whole body
BMC pattern between WT and 0,.+1- were observed throughout the reproductive period.
The lumbar spine contains much more trabecular bone and showed a different response
during the reproductive period as shown in Figure 7. For both genotypes, the BMC
declined by the end of pregnancy (-11.3 % ± 3.2 % of WT vs. -10.4 % ± 4.0 % of 0,.+1-).
The BMC declined even further during lactation to a trough value of -17.1 % ± 3.0 %
BMC in WT and -19.2 % ± 2.7 % in 0,.+1-. Both WT and 0,.+/- recovered back to
baseline level within 14 d of weaning with no significant differencc when compared with
baseline level. WT and 0,.+10 mice did not show any significant differences in lumbar
spine BMC at any time point during the reproductive cycle.
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The hind limb represents an intermediate mix of cortical and trabecular bone, and its
response to the reproductive periods differed from the whole body and spine. Relative
BMC changes at this site are shown in Figure 8. WT and 0,.+1- mice gained 20.3 % ±
3.8 % and 20.0 % ± 6.3 % respectively by late pregnancy, and the BMC significantly
decreased during lactation by about 26% to reach trough values of -6.0 % ± 3.5 % and-
7.4 % ± 2.6 % respectively (p < 0.0002). After weaning, the BMC of WT and 0/1-
increased above baseline to 6.4 % ± 3.7 % and 4.2 % ± 3.8 %, respectively, but these
were not significantly higher than baseline. There were no significant differences between
WT and 0,.+1- throughout the reproductive period.
3.4 Absolute BMC values
For clarity, the absolute whole body BMC values ofWT and O,.+I-mice during the
reproductive period are shown in Figure 9. BMC of WT declined from 0.50 I ± 0.020 at
baseline to 0.442 ± 0.010 at late lactation (p < 0.05) and BMC of 0,.+1- decreased from
0.520 ± 0.018 at baseline to 0.462 ± 0.013 at late lactation (p < 0.05). During post-
weaning recovery, the BMC of both returned to baseline level. No significant differenccs
between WT and 0,.+10 were found at any time point.
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Figure 5: BMC (g) in WT and Ctr+l- mice at Baseline. At baseline stage, BMC was
measured by DXA and showed no difference between WT and Clr+1oo
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Figure 6: Whole body BMC changes relative to BMC at Baseline throughout
reproductive period. In general, BMC increased during pregnancy, declined during
lactation, and returned to slightly above baseline after weaning. Although the BMC
excursions were significant for each genotype, no significant differences were observcd
between WT and Ctr+l- mice at any time point.
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Figure 7: Lumbar spine BMC changes relative to BMC at Baseline throughout
reproductive period. The lumbar spine BMC declined in both genotypes during
pregnancy and even further during lactation, before recovering after weaning. There were
no significant differences between WT and Ctr+l- mice at any time point.
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Figure 8: Hind limb BMC changes relative to BMC at Baseline during reproductive
period. The hind limb showed the greatest relative increase in BMC during pregnancy,
followed by a decline during lactalion, and an increase to slightly above Baseline after
weaning. No significant differences were seen between WT and Ct,.+I. mice.
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Figure 9: Absolute whole body BMC values (g) in WT and Ctr+l- mice throughout
the reproductive period. The BMC was significantly rcduced in both genotypes at latc
lactation, but recovered back to baseline after weaning. No significant difference was
notcd between WT and 0,,+1- mice at any time point.
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3.5 Serum and urine minerals assays
To investigate in vivo minerals changes that are closely related to BMC changes, I
conducted several mineral assays including serum and urine calcium, serum and urine
phosphorus and serum and urine magnesium.
3.5.1 Serum total calcium
Scrum total calcium concentrations of both WT and 0,.+10 mice throughout thc
reproductive period are shown in Figure 10. Normally, mice serum calcium level does not
significantly change during the reproductive period. WT and 0,.+1- maintained serum total
calcium concentration within the range of2.1 to 2.4. There was no significant diffcrcncc
between WT and 0,.+1- mice at any time point.
3.5.2 Urine calcium
Urine calcium concentrations normalized to urine creatinine are shown in Figure II.
Calcium excretion usually increases during pregnancy due to absorptive hypercalciuria,
and decreases during lactation by the effect ofPTHrP, which increases calcium renal
reabsorption. In this experiment, urine calcium did not incrcase during pregnancy, but it
did decline significantly during lactation to 0.3 ± 0.1 in WT and 0.4 ± 0.1 in 0,.+1- (p <
0.05 compared with Baseline). 0,.+1- mice tended to excrete less calcium in urinc than
WT at late pregnancy (1.1 ± 0.2 of WT vs. 0.7 ± 0.3 of C,,·+I-, p = not significant). By thc
end of lactation and during post-weaning recovery, urine calcium was similar to Basclinc
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in both genotypes. No significant differences of urine calcium were observed between
WT and 0,.+1- at any time point.
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Figure 10: Serum total calcium in WT and Ctr+l- mice throughout reproductive
period. Serum total calcium remained relatively stable at every time point during the
reproductive period in both groups. WT and Or+l- mice shared the same pattern of serum
total calcium without any signiticant difference between them.
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Figure 11: Urine calcium in WT and 0,+1- mice during reproductive period. Both
genotypes had significantly reduced urine calcium excretion during early lactation. No
significant differences were observed between WT and 0,.+1- mice at any time point
throughout the reproductive period.
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3.5.3 Serum phosphorus
Serum phosphorus concentrations of WT and Clr+l- mice are shown in Figure 12.
Phosphorus was unchanged at late pregnancy, but was significantly decreased in both
genotypes at late lactation. WT phosphorus concentration declined from 2.5 ± 0.1 to 2.1 ±
0.1, while Clr+l- phosphorus fell from 2.5 ± 0.1 to 2.0 ± 0.1 (p < 0.05). During post-
weaning recovery, the serum phosphorus was normal in both genotypes, although in Cir+l•
mice the serum phosphorus was significantly lower at recovery I than at recovery 2 (2.4 ±
0.1 vs. 2.8 ± 0.2, p < 0.05). There were no significant differences between WT and Co·+I.
mice during the reproductive period.
3.5.4 Urine phosphorus
Urine phosphorus values are shown in Figure 13. WT and Clr+l• mice had the same trend
in urine phosphorus changes during the period except at late pregnancy. WT urine
phosphorus was unchanged in late pregnancy while Clr+l- mice showed a significantly
decreased urine phosphorus concentration (11.0 ± 2.2 ofWT vs. 4.4 ± 1.4 of Co·+I., p <
0.05). As expected, urine phosphorus by late lactation was significantly increased in WT
and Clr+I., reaching peak values of 30.1 ± 3.5 and 26.6 ± 6.5, respectively. After lactation,
urine phosphorus returned to the Baseline level in both groups.
3.5.5 Serum magnesium
Serum magnesium concentrations are shown in Figure 14. One small but significant
difference was measured. Changes for serum magnesium increased in Clr+l- mice Ii'om
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1.2 ± 0.0 at baseline to 1.4 ± 0.1 at late pregnancy (p < 0.05). There were no other
significant differences within or between genotypes at any time point.
3.5.6 Urine magnesium measurement
Urine magnesium values are shown in Figure 15. WT mice showed significantly
increased urine magnesium excretion at late pregnancy (7.9 ± 0.9 at Baseline vs. 12.9 ±
1.0, p < 0.05), but no increase occurred in Ctr+l- mice. Both genotypes had significantly
elevated urine magnesium by late lactation, which returned to baseline values by recovery
1. The urine magnesium significantly increased again at recovery 2 and 3. No significant
differences were observed between WT and Ctr+l- from baseline to recovery 3.
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Figure 12: Serum phosphorus in WT and 01'+1- miee throughout the reproductive
period. Both had reduced serum phosphorus concentrations at late lactation when
compared with baseline (p < 0.05). Serum phosphorus in 01'+1- mice seemed to lag behind
WT in returning to the baseline level during post-weaning recovery. There were no
significant differences between WT and 01'+1- mice at any time point.
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Figure 13: Urine phosphorus in WT and Ctr+l - mice throughout the rcp.-oductive
period. Urine phosphorus in 0,.+1- was significantly lower than that found in WT at late
pregnancy. Both WT and 0,·+1- experienced high urine phosphorus excretion at late
lactation (p < 0.05), and then the urine phosphorus levels went down to baseline levels
during recovery after lactation.
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Figure 14: Serum magnesium in WT and Ctr+l- mice throughout reproductive period.
Or+l - mice had slightly higher serum magnesium in late pregnancy when comparcd with
baseline (p < 0.05). There were no significant differences in serum magnesium
concentration between WT and Or+l- mice at any timc point.
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Figure 15: Urine magnesium in WT and Ctr+l- throughout the reproductive pedod.
WT mice increased urine magnesium excretion during pregnancy (p < 0.05) whereas no
significant increase occurred in Clr+l- mice. Both groups had higher urine magnesium
concentrations at late lactation versus baseline (p < 0.05) and at recovery 2 and recovery 3
versus baseline. There were no significant differences between WT and Clr+l. at any time
point.
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3.6 Markers of bone turnover assays
Bone turnover markers reflect the relative activity of bone formation and resorption. A
serum bone formation marker (P1NP) and a urine bone resorption marker (OPD) were
measured.
3.6.1 Serum PINP assay
Serum PINP concentrations ofWT and 0,.+1- mice throughout the reproductivc period
were shown in Figure 16. P1NP remained at Baseline level during pregnancy and early
lactation in both genotypes before increasing significantly at late lactation (197.6 ± 46.1
in WT vs. 193.3 ± 22.3 in 0,.+1-) and recovery I (136.9 ± 29.6 in WT vs. 375.3 ± 176.5 in
0,.+1-) when compared with baseline (66.4 ± 12.5 in WT vs. 51.9 ± 11.4 in 0,.+1-). WT
and 0,.+1- showed the same pattern of serum PINP changes during the reproductive
period without any significant differences between them.
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Figure 16: Serum PINP in WT and Ctr+l- mice throughout the reproductive period.
WT and Or+l- mice showed normal PINP during pregnancy and early lactation, but high
serum PINP at late lactation (p < 0.05). PINP remained at a significantly high Icvcl in
WT mice during recovery I (p < 0.05). Although the large error bar made the high PINP
at recovery I in Or+l- mice non-significant, it was still considered a high level. After
recovery I, PINP returned to the baseline level in both genotypes. No significant
differences in serum PINP between WTand Cf/·+I- were observed.
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3.6.2 UrineOPO
Urine OPO concentrations are shown in Figure 17. Bone resorption increases during
lactation, and this was confirmed by increased urine OPO excretion in WT and Or+l-
mice at early lactation, which became statistically significant at late lactation. Urine OPO
increased even further in WT and Or+l- mice at recovery 1. WT and Or+l- mice did not
have any significant differences between them at any time point.
3.6.3 Serum PTH
Serum PTI-! values are shown in Figure 18. PTI-[ usually decreases during pregnancy and
lactation. In this study, however, PTH increased significantly in both WT and Or+l- mice
during pregnancy and remained elevated during lactation and post-weaning recovery.
Although WT mice seemed to have higher PTH than Or+l- at Baseline (31.6 ± 11.5 in WT
and 10.6 ± 4.7 in C/J·+I-), the difference was not statistically significant at that or any other
time point.
3.7 Milk calcium content
Since an absence of calcitonin altered milk calcium content and Or is expressed by
lactating mammary tissues, milk calcium was assayed in WT and Or+l- mice and
normalized to milk protein content. The results are shown in Figure 19. No significant
difference was detected between the two genotypes.
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Figure 17: Urine DPD in WT and Ct,+I- mice during the reproductive period. In both
genotypes, DrD increased during early and late lactation, and increased further during
post-weaning recovery. WT and 0,.+1- did not show any significant differences at any
time point.
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Figure 18: Serum PTH in WT and Ctr+l- mice throughout the reproductive period.
Although a decrease in PTH was expected during pregnancy and lactation, in both
genotypes PTI-I increased and remained elevated through recovery 1. No significant
differences between WT and C/t·+I- mice were observed.
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Figure 19: Milk calcium content normalized to milk protein in WT and Ctr+l• mice at
cady lactation. No significant differences between WT and 01'+1. mice were observed.
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3.8 Micro computed tomographic (~lCT) analysis of tibias
Considering that there were no significant differences in BMC changes between WT and
Ctr+l. mice throughout the reproductive period, micro computed tomographic (IlCT)
analysis was used to determine whether the two genotypes experienced any different
trabecular bone microstructure changes between baseline and late lactation. The results
are shown in Table 1. Consistent with increased bone resorption leading to net bone loss,
both the WT and Ctr+l- group had significantly decreased mean trabecular thickness
(MTT), increased trabecular separation, and decreased bone volume/tissue volume
(BV/TV) at late lactation (p < 0.05). In contrast, bone volume increased by late lactation,
and the difference was significant in Ctr+l- mice (0.47 ± 0.03 at late lactation vs. 0.36 ±
0.02 at baseline, p < 0.05). The two genotypes also had significantly increased bone
surface and tissue volume (TV) at late lactation when compared with baseline (p < 0.05).
No significant differences were detected between WT and Ctr+l-mice in any of these
parameters.
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Table 1: Micro computed tomographic changes in WT and Ctr+l - mice at baseline and late lactation
(LL)
Veterbrae MTT().lm) MTS().lm) BV(mm3) TV (mm3) BV/TV (%) BS(mm2)
WTbaseline 53.31 ± 1.31" 183.59± 5.25 0.33 ± 0.02 l.76± 0.11" 19.07± 0.97 26.03 ± 1.45"
(5)
WTLL(5) 48.90± 0.61" 206.46± 17.25 0.43 ± 0.04 2.80±0.33" 15.72± 1.64 37.84± 3.02"
0,.+1- baseline 51.99± 0.73 b 194.65 ± 7.36 0.36± 0.02" 1.99 ± 0.09b 17.95 ± 1.12" 28.40± 1.19b
(5)
0,.+1- LL (5) 49.16± 0.22b 207.94±4.43 0.47± 0.03" 3.17± 0.21 b 14.93 ± 0.48" 41.95 ± 2.54b
).leT analysis revealed that both genotypes had significantly decreased trabecular bone thickness and increased bone surface
at Late Lactation than they had at Baseline stage. 0,.+1- mice had increased bone volume but not WT. MTT- mean trabecular
thickness, MTS-mean trabecular separation, BV- trabecular bone volume, TV - total volume, BV/TV- trabecular bone
volume relative to total volume, BS - trabecular bone surface. Shared letters within columns indicate statistical significance
(p < 0.05). The results were expressed as Mean number ± SE.
3.9 Biomechanical tests
3.9.1 3-point bend (3PB) test
Tibias from WT and 0,.+1- mice at baseline and late lactation were used to test cortical
bone strength. Results are shown in Table 2. The ultimate load of force required to break
tibias in both WT and 0,.+1- was significantly less at late lactation than that at baseline (p
< 0.05). Consistent with this indication of weaker bone, the tibias of the two genotypes
also had reduced stiffness and absorbed less energy prior to breakage. Displacement
(distance moved before breakage) also increased in both genotypes, but was significant
only in 0,.+1- mice. No significant differences were found between WT and 0,.+1-.
3.9.2 Reference point indentation test
The reference point indentation test is a relatively new procedure that tests cortical bonc
strength by reversibly deforming the cortical surface with a microprobe. It has not becn
tested during lactation, and so this experiment was a trial to determine if the procedurc
could detect a difference between baseline and end-of-lactation bone strength. Tibias and
vcrtebrae from WT at baseline and late lactation were analyzed; the company declincd to
analyze bones from 0,.+1- mice. Using a standard 2N force, no significant differences in
cortical bone strength as indicated by indentation distance increase were detected between
baseline and late lactation, with 4.0 ± 0.3 and 5.0 ± 0.5 respectively. However, there was
a trend for greater indentation distance, which is the expected result ifcortical bonc
strcngth is reduced at the end of lactation. Results are shown in Figure 20. The
experiment was repeated with a potentially deforming force of3N and the results wcrc
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similar and not statistically significant (not shown). The vertebrae could not be reliably
measured due to little resistance to the probe, and so no data were obtained rrom that
analysis.
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~Table 2: 3-point bend (3PB) test oftibia between WT and Ctr+/- at baseline and late lactation
(LL)
Genotype and stage I Ultimate load (gf) Displacement (11m) Stiffness (gf/mm) Energy absorbed
(gf/mm2)
WT baseline (4) 2.00 ± O.lOa O.4S ± 0.08 9.77± O.4Sa 0.64± 0.03a
WTLL (7) 1.37± 0.12a 0.67±0.13 7.44± 0.6l a 0.44 ± 0.04a
Ctr+/- baseline (S) 1.80± 0.10b O.34±0.OSa 9.S8± 0.S2b 0.S7±0.03b
Ctr+/-LL (8) 1.33 ± 0.10b 0.78 ± 0.11 a 7.73 ± 0.44b 0.42 ± 0.03 b
3PB test showed that both WT and Ctr+/- mice had weaker bone strength at late lactation than at baseline.
Both genotypes had the same trend of bone strength change from baseline to lactation, without any significant
difference between them. Shared letters within columns indicate statistical significance (p < O.OS). The results
were expressed as Mean ± SE.
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Figure 20: Indentation distance increase of tibias at baseline and late lactation in
WT mice. No significant differences in bone strength were found between baseline and
latelactationinWTmice.
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3.10 Or mRNA expression analysis
R A was extracted from bone to determine if CTR mRNA expression is reduced in 0,.+1-
mice, as was previously shown in other osteoclasts derived from 0,.+1- mice studied in
vi/roo Real-time quantitative RT-PCR results were analyzed using the T"'6Ct method (see
rigure 2\). CTR Ct normalized to GAPDH Ct was used as the indicator of CTR mRNI\
expression, and the results were normalized to the WT values. No significant fold change
was observed between WT and 0,.+1- mice, indicating no difference in CTR mRNA
expression.
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Figure 21: Tibial expression of CTR mRNA in WT and Ctr+l- at baseline. Real-timc
quantitative RT-PCR showed no significant difference in Or mRNA expression between
WT and Or+/- mice. Tests were conducted in triplicate and normalized to Gapdh and thc
WTvalue.
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4 Discussion
Calcitonin plays an important role in normal calcium and bone metabolism during
lactation, since O/cgrp null mice lacking calcitonin experience more BMC loss during
lactation than WT mice (77). Thus calcitonin is physiologically important because it
prevents excessive bone resorption during lactation. Whether the same is true in humans
is unknown. In this project, I investigated Or+l - mice to determine whethcr partial loss of
the Or gene causes the same phenotypes as a loss of calcitonin.
4.1 Phenotypes in mice during the reproductive period
Since bone contains a large amount of mineral, changes in BMC reflect changes in thc
amount of bone due to formation or resorption. Bone contains 99% of the body's calcium,
ovcr 85% of its phosphorus, and 66% of its magnesium. Calcium and phosphorus form
hydroxyapatite crystals in bone (84, 120). Together with alterations in circulating levels
of bone formation and resorption markers, serum and urine levels of these three minerals
can be used as indirect indicators of bone metabolism (99).
The BMC scanning experiments were conducted beginning 10 wk after the micc wcre
born, thus ensuring that the experimental mice had reached peak bone mass (121). WT
and Cu·+I- mice showed a relatively stable BMC after reaching peak bone mass. At
baseline, there was no significant difference between the two with BMC of 0.501 gin WT
and 0.520 g in C/I·+1-. MicroCT also showed no significant difference in bone phenotypcs
between the genotypes at baseline. These findings by DXA and microCT differ from thc
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only prior published report, in which Or+l- mice were found by microCT to have a highcr
bonc mass than WT. Since, in my studies, sister WT and Or+l- mice were compared, it
could be concluded that there was no difference between the WT and Or+l- micc. Othcr
parameters were also not different between WT and Or+I-, including urine and serum
minerals, and bone formation and resorption markers. A previous study in our group
showed that Blackswiss calcitonin null mice also had the same BMC as WT mice (77).
These results may indicate that calcitonin and CTR play unimportant roles in cstablishing
peak bone mass, since absence of the ligand does not alter bone mass in virgin femalcs by
10 wk of age (77).
During pregnancy in mammals, the mother provides calcium for fetal development (99).
In order to maintain maternal serum calcium homeostasis, bone may be resorbed to
release calcium. However, in my experiments, I observed that a relative change in bone
metabolism during pregnancy was an increase in BMC. This may be an adaptation of
mammals to store calcium in preparation for the demand of calcium for milk production.
The rate of intestinal calcium absorption increases during pregnancy. This helps providc
calcium to the fetus and also makes calcium available for the maternal skeleton to
increase BMC (105). Both WT and CIi·+I- mice had an increase in BMC of the whole body,
with a 7.4% increase in WT and 7.7% increase in Or+I-. In contrast, the lumbar spine lost
BMC during pregnancy in both WT and Or+l- mice while the hind limb gained BMC. The
whole body measurement largely reflects changes in cortical bone, while lumbar spinc
and hind limb contain a mix of trabecular and cortical bone. Thc lumbar spine contains
the largest proportion of trabecular bone. Trabecular bone has much more surface area
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than cortical bone, enabling osteoclasts to resorb this form of bone more rapidly than
cortical bone. Why the spine resorbs during pregnancy while the whole body and hind
limb are gaining BMC is unclear. We have previously found that genetic differences are
likely a factor, since Blackswiss mice gain BMC at the whole body level and spine during
pregnancy, while C57BLl6 mice (the same strain that 0,.+1- mice are in) gain BMC at thc
whole body level and lose it at the spine during pregnancy (77). The gain in BMC at the
hind limb may be a response to increased body weight (increased loading response)
during pregnancy that must be borne by the limbs.
During lactation, calcium is required for milk production (99). WT and C/i·+I- mice lost
BMC of the whole body to maintain maternal serum calcium homeostasis, with a 10.7%
decrease in WT and 10.6% decrease in 0,.+1- mice, respectively. A further decline in
BMC occurred at the lumbar spine during lactation, and the hind limb also lost BMC.
Bone resorption releases minerals into serum, and, during lactation, these minerals will
either go into milk, be excreted into the urine, or return to the skeleton in the form of
newly mineralized bone (99). Urine calcium excretion decreased in both genotypes
throughout early lactation and remained low during late lactation, indicating that calcium
was not being lost in the urine but instead was being used to produce milk. In contrast,
urine phosphorus and magnesium excretion were significantly increased during latc
lactation. Although hydroxyapatite contains twice as much calcium as phosphorus, it is
evident that much of the phosphorus released from bone is not needed for milk production.
The excess phosphorus and magnesium released from bone during lactation are excretcd
into the urine. The bone formation marker PINP and bone resorption marker DPD
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increased significantly during lactation in both WT and 0,.+1- mice, confirming that bone
turnover was increased. In fact, both increased bone formation and resorption occur
during lactation, with resorption exceeding formation, to lead to a net loss of bone as
shown by the changes seen in BMC by OXA and by microCT. OPO increases the most
during the first ten days of lactation, but this time point was not measured in these
experiments; thus the highest level of OPO was not seen nor was the imbalance between
resorption and formation markers at this time point. I focused on the end of lactation time
point to detect the maximal change in BMC that results, and not the mid-point of lactation
when bone resorption occurs at the maximal rate.
The microCT results showed that vertebrae, which are largely composed of trabecular
bone, had a significantly increased bone surface area along with a decreased thickness,
which is consistent with more osteoclasts resorbing bone when compared to the baselinc.
Despite the net loss of bone mass, the total volume and bone volume increased by late
lactation, whereas the BV/TV decreased as expected (77). This increase in total volumc
has been observed before in lactating rodents and may be a form of compcnsation for the
loss of bone strength during lactation (77,122,123). It implies that periostcal bone
formation occurred during pregnancy and lactation to increase the total volume of bone
while endosteal resorption occurred during lactation. Consequently, even though less
bonc is present, the increased bone volume offsets the decline in bone strength somewhat,
since a wider cylinder is inherently stronger than a narrower cylinder of the samc mass.
But, despite this increase in bone volume, bone strength at late lactation was still reduced,
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as indicated by the 3PB test. Conceivably, bone strength would have been reduced even
further had the compensatory increase in bone volume not occurred.
Ctr+l- mice displayed a significant increase of total volume and bone volume at Late
Lactation, while, in WT mice, the increase in total volume was significant, and the
increase in bone volume just escaped statistical significance. In both genotypes, the
decline in BV/TV was statistically significant. Although there was no direct evidence
showing that Ctr+l- lost more bone than WT, it is reasonable to speculate that bone
microstructure in Ctr+l- was weakened more than in WT during lactation, necessitating a
greater compensatory increase in bone volume. However, since there were no other
differences in bone mass, strength, or volume between WT and Ctr+l- mice at any other
time point, it is possible that this is a chance finding and not a true difference. Given the
trend in bone volume of WT mice to increase by a similar magnitude as in Ctr+l- mice, it
seems most likely that WT and Ctr+l- mice experienced the same changes in bone mass
during pregnancy and lactation.
Besides the 3PB test, we also investigated the use of the novel reference point indentation
test to analyze cortical bone strength change from baseline to late lactation as a trial
analysis to validate the technique. However, we found this technique was not as good as
the 3PB test for cortical bone strength analysis because it could not distinguish a
difference in bone strength of tibia between baseline and late lactation in WT mice,
whereas the 3PB test could. Reference point indentation could not be used on vcrtcbrac at
all because the bone was not strong enough even at baseline to yield a consistent result.
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BMC in both WT and Ctr+l- mice recovered back to baseline after the bone loss
experienced during lactation. A previous study in our group showed that BMC in
calcitonin null mice, which lost twice as much BMC as in WT, were able to recover to the
non-pregnant level, although the recovery process took just several more days than in WT
mice (77). My experimental results show that only one allele of the calcitonin receptor
gene is required for post-weaning bone recovery to be achieved. BMC values reached by
the end of the post-weaning period were actually increased when compared with the non-
pregnant BMC value (shown by Figure 6 - Figure 8). One explanation of this is that the
mice had increased BMC with age. Based on previous studies, the recovery period of
mice is 3 weeks (21 days) (77). BMC quickly recovered to Baseline level after weaning,
and this process usually did not take 3 weeks. Once it reached the baseline level within 3
weeks, BMC kept increasing. BMC data was obtained at the end of each week during
recovery. The highest BMC result was used to indicate the level to which bone had
recovered, shown in Figure 6 - Figure 8. Although the mean values of absolute BMC
values were increased post-weaning over baseline, for both genotypes the difference was
non-significant.
Urine and serum minerals remained at the non-pregnant level during post-weaning
recovery, except that renal magnesium excretion increased during Recovery 2 and 3
stages. This may be a chance finding, or it may indicate that more magnesium is being
absorbed during post-weaning than is required to mineralize the new bone that is bcing
formed. Bone formation and resorption markers were highly increased in both genotypes
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during early post-weaning recovery, confirming that bone turnover stays at a higher rate
compared to the non-pregnant period. Although bone formation and resorption markers
are both increased during early post-weaning recovery, the net effect is the opposite from
lactation, with the rate of bone formation exceeding that of bone resorption.
4.2 Roles of Or in renal phosphorus excretion at late pregnancy
Thc only significant difference between WT and Or+l- mice was in a significantly
decreased urine phosphorus excretion in Or+l-mice at late pregnancy, and this was
accompanied by a trend for reduced excretion of calcium and magnesium, as well. These
results may indicate that loss of one copy of the Or gene may be sufficient to impair
urine phosphorus excretion at late pregnancy, during a time when the net intestinal
absorption of phosphorus is likely increased. Or is expressed in renal tubules, where it is
known to playa role in renal mineral excretion. The evidence regarding the function of
calcitonin in renal phosphorus handling is quite controversial. One study by Dr. Insogna's
group showed that calcitonin administration in X-linked hypophosphatemia increascd
serum phosphorus and suppressed circulating FGF23, which could increase phosphorus
excretion (124). However, another study suggested that calcitonin could inhibit
phosphorus reabsorption (125). One example given was that a renal tubular cell line from
an American opossum stably transfected with the calcitonin receptor had inhibited
intracellular phosphorus reabsorption (more phosphorus loss in urine). But this inhibition
is in a tubular cell line specific manner (126). Although I found that haploinsufficiency of
Or did not alter Or mRNA expression in bone, the same may not be true of kidneys.
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Future work will look at Or gene expression in the kidney to see whether
haploinsufficiency 01'01' would significantly change the expression levcl. The lack of
one copy of the Or might lead 01'+1- mice to have impaired renal mineral excretion
during late pregnancy, a time when intestinal mineral absorption is increased such that thc
rcnal filtered load of these minerals is also increased.
PTl-l and FGF23 each increase renal phosphorus excretion. During late pregnancy, therc
was no significant difference in serum PTI-! between WT and 01'+/., and so it seems
unlikely that altered PTH explains the difference in renal phosphorus excretion in WT
and C/t·+I. mice. Future work should examine FGF23 and its soluble co-receptor Klotho at
late pregnancy between WT and C/t·+I- to determine whether haploinsufficiency of Or
leads to altered FGF23 physiology, which could, in turn, alter renal phosphorus excrction.
First, serum FGF23 concentration and FGF23 expression at bone tissue in 01'+1- micc will
be examined; second, mechanisms of how CTR and FGF23 interact with each other will
be studied.
4.3 Parathyroid hormone during reproductive period
PTH and PTHrP both activate the RANKL-RANK pathway to induce osteoclast-mediated
bone resorption (44,46,47). They have a similar N-terminal structure, enabling both to
act on the PTHR. In non-pregnant adults, low serum calcium stimulates synthesis and
release ofPTH to increase calcium rclease from bone. In lactating humans, PTH remains
at non-pregnant levels or decreases, while PTHrP production is highly incrcased in
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mammary tissue and causes an increase in the circulating PTHrP concentration, as well
(107). High PTHrP combines with low estradiol to enhance bone resorption and thereby
provide sufficient calcium for milk production. PTHrP measurements are not easily
obtained in mice, and so, in this project, I only measured serum PTH.
PTH was measured at baseline, late pregnancy, late lactation, and recovery 1. No
significant differences were detected between WT and Or+/- mice. Within the WT group,
there was no signiticant difference at any time point, while Or+/- mice had significantly
increased PTH at late pregnancy and recovery 1. An increasing trend in PTH levels from
baseline to late lactation was observed in both genotypes. Sample size in this experimcnt
was relatively low, with only 5 samples in each experimental group. These findings
contrast with the decline in PTH that we have previously observed during pregnancy and
lactation in WT mice, and it is unclear why these new data differ from what has
previously been obtained in our group (118). Genetic differences are possible, although
we have observed a decline in PTH in both Blackswiss and C57 strains in prior
experiments. Certainly, the loss of calcium in milk and a low dietary calcium intake can
stimulate PTH to increase during lactation, thereby resorbing bone to maintain maternal
serum calcium within the normal range. However, the mice in these experiments were
maintained on the same diet and conditions that prior mice received in our laboratory, and
so the lack of suppression of PTl-l remains unexplained.
Several reasons may explain the difference in serum PTH change pattern from baseline to
late lactation between WT and Or+/- mice. First, the loss of one copy of Or might
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enhance renal calcium excretion, and a loss of calcium in the urine should lead to a lowcr
serum calcium. In turn, a trend for lower serum calcium will trigger PTH release to
restore the serum calcium to normal through PTH's effects on renal tubular calcium
handling, bone resorption, and stimulation of calcitriol production. However, urine
calcium analysis throughout the reproductive period indicated that 0,.+1- mice did not
have significantly higher urine calcium than WT mice at any time point. Therefore, this
possibility was reasonably excluded, conceding the limitations that random urinc samplcs
havc when compared to the more thorough collection of all urine when mice arc
maintained in metabolic cages. Second, Or+l- might have reduced intestinal calcium
absorption, which caused PTH release to stabilize the serum calcium. This explanation
was supported by an experiment in 1986 showing that calcitonin elevated calcitriol
production, thus increasing intestinal calcium absorption (127). Loss of one copy of 0,.
may impair calcitriol formation and intestinal calcium absorption, which, in turn, would
stimulate a compensatory increase in PTH production throughout reproductive cyclc.
4.4 Comparison between Or+l- and Calcitonin (O/cglp) knockout mice throughout thc
reproductive period
The objective of this research project was to determine whether loss of Or causes the
same phonotype as loss of the ligand calcitonin. However, Or null mice do not usually
survive gestation, and so CII·+I-mice had to be used to compare with WT mice. Studies by
Dr. Galson's group (the group that generated these mice) using real-time quantitativc
PCR, showed that haploinsufficiency of Or caused a two-fold reduction in 0,. expression
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in osteoclasts cultured in vitro (19). This result was encouraging that 01'+1- mice would
have a phenotype due to reduced Or mRNA expression. But, after finding no difference
in the phenotype between WT and 01'+1- mice in my experiments, I then analyzed Or
mRNA expression in vivo, extracted from tibias, and found that WT and 01'+1- mice had
the same Or mRNA expression level. Since I measured the Or expression in the
harvested bone tissue directly, this result is more relevant than Or expression in cultured
osteoclasts. Another potential reason why my Or expression result is different from the
one of Or. Galson's group is that only female mice were used in my research work.
Although, in the published paper, it does not mention that both genders were utilized in
the study, the possibility that phenotypic differences between male and female mice affect
Or expression cannot be excluded (19). Or is expressed not only at osteoclasts in bone
but also at mammary gland tissue and the pituitary gland. In the mammary gland, the
calcitonin/calcitonin receptor signaling pathway appears to suppress PTI-IrP expression.
PTI-IrP can induce bone resorption during lactation. In the pituitary gland, the pathway
may reduce prolactin. Prolactin causes estrogen deficiency and stimulation of PTl-lrP
expression. Therefore, analysis of Or gene expression at pituitary and mammary gland
tissue is necessary as well in the future.
Previous studies showed that calcitonin null mice lost significantly more BMC than WT
mice during lactation at the whole body, lumbar spine and tibia regions (77). This was
supported by urine OPO analysis, which showed that the null mice had significantly
higher OPO than WT mice at late lactation, but these phenotypes were not observed in
01'+1- mice. Bone microarchitecture analysis by ~lCT also did not find any difference
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between WT and Or+l- mice at any time point. The same result was observed in bone
strength, with no difference between WT and Or+l- mice. The reason for the lack ofa
difference in phenotype between WT and Or+l- mice is likely because loss of one copy of
the gene did not affect Or gene expression in vivo. BMC of both Or+l- and calcitonin null
mice could recover to baseline level after lactation. This result confirmed, to some extent,
that calcitonin signaling through CTR was not required for post-weaning recovery.
It is also possible that serum calcitonin itself could upregulate in response to
haploinsufficiency of CTR. However, [ did not examine such a possibility at this point
because the time needed to collect more serum was not available. However, serum
calcitonin level will be measured throughout these main time points of the reproductive
cycle. [fserum calcitonin is higher in Or+l-than in WT mice, it will be evidence of
compensation for the loss of one allele of Or gene.
4.5 Future work
4.5.1 Exploration of Or knockout mice on Blackswiss strain
We have previously found that the Blackswiss strain, in which the CT mice wcre studied,
rescues the phenotype of some knockout mice, which would otherwise die in utero,
including the PTH/PTHrP receptor null mice. It is possible that the phenotype of Or+l-
mice may differ in the Blackswiss background when compared to C57, given that
Blackswiss mice begin with a higher bone mass and lose much more bone mass during
lactation than C57 mice do. Since few Or null mice survive to birth in the C57 mice
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strain and the reason for this early mortality is unknown, the CTR colony is being back-
crossed into the BlackSwiss background to determine if Clr null mice will survive to
adulthood. If Clr null mice do not survive, Clr+l - mice in the Blackswiss background will
still be studied to determine if loss of one copy of the gene alters the phenotype during
pregnancy and lactation as compared to WT mice.
4.5.2 Knockdown experiments
Ifcrossing Clr mice into Blackswiss does not result in any Clr null mice surviving, and if
C,,·+I- mice in that genotype continue to have no distinctive phenotype, alternative
approaches may be developed. Options include tlying to knock down the expression of
Clr in Clr+l - mice during lactation by using antibodies or siRNAs; however, the Icngth of
time required for knockdown in the whole animal during lactation seems prohibitive and
unlikely to succeed. Instead, another option would be to create a conditional knockout of
Clr that is not induced until after birth. This should really be a global knockout of the Clr
after birth in order to ensure that the Clr is knocked out in all tissues, and so an induciblc
Cre, such as with the Tet-On/Tet-Off system, could be used. Cre is a DNA recombinase
that specifically recognizes the 10xP sequences in a genome. In the presence of Cre, DNA
recombination occurs between the 10xP sites, deleting genes between the 10xP sites. After
Cre is transfected into the genome, if 10xP sequences are inserted at either end of a critical
exon of Clr using knock-in techniques, the expression of Cre can silence Clr expression.
The Tet-On/Tet-Offsystem can be used to control the expression ofCre. Chemicals such
as tetracycline or doxycycline regulate the Tet-On/Tet-Off system. By using the form of
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Tctthat is always off unless the drug is present, normal Or expression will be maintained
during fetal development through adolescence. Then, doxycycline can be administcrcd to
promote Cre expression and eliminate the expression of Or in the adult mouse prior to
mating. In this way, the combination ofCre and the Tet-On/Tet-Offsystem may cnable a
global knockout of the Or after birth. An osteoclast-specific knockout of Or would not
be as useful at first because the phenotype of O/Cgrp null mice may be the result of loss
of calcitonin action in multiple tissues (pituitary, mammary, bone) and not just in bonc.
4.5.3 Alternative global Ctr knockout that already exists
One research group in Australia created a global inducible Or knockout that shows
normal postnatal survival (128). Those investigators used the Cre system under the
control of Cytomegalovirus (CMV) promoter. The CMV promoter was coupled with the
Tet-On/Tet-Offsystem, which regulated the activity of the CMV promoter (129).
Inscrtion ofloxP sequences at Exon 13, Exon 14 and the 3' untranslated region (3' UTR)
of Or enabled Cre-mediated suppression of the gene. During fetal dcvelopment, thc
CMV promoter was inhibited, leading to no Cre expression. Thus Or had normal
expression, and the fetus survived. After birth, the activity of the CMV promoter was
cnhanced by regulating the Tet-On/Tet-Off system, thus making Cre largely expressed.
The expression ofCre inactivated normal Or expression by recombining thc region
between loxP sequences. This enabled the global knockout of Or in micc. Real-timc PCR
showed that Or expression was reduced by over 94%, but not 100%. This animal modcl
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is the best option for studying CTR function during pregnancy and lactation. The only
problem is that the investigators have been reluctant to share this model with anyone else.
4.6 Conclusion
WT and Ctr+/- underwent similar changes in bone mass, bone microarchitecture,
calciotropic hormones, and serum and urine minerals during pregnancy and lactation.
After lactation, the skeleton of each genotype recovered fully and quickly.
The loss of one copy of the calcitonin receptor gene did not cause the same phenotype
that complete loss of the ligand caused in mice. It may simply be that the loss of one copy
is not sufficient to impair calcitonin's role in regulating bone metabolism, especially
given that Ctr mRNA expression was normal in the tibias of Ctr+/- mice. Further work
will be needed to study (and generate, if necessary) a model that results in global loss of
Ctr in animals that survive post natally.
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